{"id":"chembl-chembl1200796","rwe":[{"pmid":"41904946","year":"2026","title":"Autoimmune Encephalitis in Acute Care-Pathology, Diagnosis, and Management.","finding":"","journal":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","studyType":"Clinical Study"},{"pmid":"41904851","year":"2026","title":"IL-17/Th17-Treg Axis regulation by Huangqi Gancao decoction in immunosuppression: Integrating network pharmacology, metabolomics, and in vivo validation.","finding":"","journal":"Journal of chromatography. B, Analytical technologies in the biomedical and life sciences","studyType":"Clinical Study"},{"pmid":"41904054","year":"2026","title":"Germ layer specification and organotropism in lymphoma invasion.","finding":"","journal":"Science bulletin","studyType":"Clinical Study"},{"pmid":"41902667","year":"2026","title":"Electroacupuncture Ameliorates Cyclophosphamide-Induced Ovarian Impairment in Rats With Diminished Ovarian Reserve and is Associated With Th17/Treg-Related Immune Modulation.","finding":"","journal":"Mediators of inflammation","studyType":"Clinical Study"},{"pmid":"41899096","year":"2026","title":"Identification of Drug Repurposing Opportunities of Immunomodulatory Drugs for Inflammatory Bowel Disease Through Inverse Pharmacovigilance Signal Detection in the FAERS Database.","finding":"","journal":"Journal of clinical medicine","studyType":"Clinical Study"}],"_fda":{"id":"29b88d00-eeea-7282-e063-6294a90a4024","set_id":"02e64046-687d-449e-e063-6294a90a6c32","openfda":{"upc":["0339822025510","0339822025015","0339822026012"],"unii":["8N3DW7272P"],"route":["INTRAVENOUS","ORAL"],"rxcui":["1734917","1734919","1734921"],"spl_id":["29b88d00-eeea-7282-e063-6294a90a4024"],"brand_name":["CYCLOPHOSPHAMIDE"],"spl_set_id":["02e64046-687d-449e-e063-6294a90a6c32"],"package_ndc":["39822-0255-1","39822-0250-1","39822-0260-1"],"product_ndc":["39822-0250","39822-0255","39822-0260"],"generic_name":["CYCLOPHOSPHAMIDE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["CYCLOPHOSPHAMIDE"],"manufacturer_name":["XGen Pharmaceuticals DJB, Inc."],"application_number":["ANDA211757"],"is_original_packager":[true]},"version":"4","pregnancy":["8.1 Pregnancy Risk Summary Based on its mechanism of action and published reports of effects in pregnant patients or animals, cyclophosphamide for injection can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology ( 12.1 ) and Nonclinical Toxicology ( 13.1 )]. Exposure to cyclophosphamide during pregnancy may cause fetal malformations, miscarriage, fetal growth retardation, and toxic effects in the newborn [see Data] . Cyclophosphamide is teratogenic and embryo-fetal toxic in mice, rats, rabbits and monkeys [see Data] . Advise pregnant women and females of reproductive potential of the potential risk to the fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects is 2%-4% and miscarriage is 15%-20% of clinically recognized pregnancies. Data Human Data Malformations of the skeleton, palate, limbs and eyes as well as miscarriage have been reported after exposure to cyclophosphamide in the first trimester. Fetal growth retardation and toxic effects manifesting in the newborn, including leukopenia, anemia, pancytopenia, severe bone marrow hypoplasia, and gastroenteritis have been reported after exposure to cyclophosphamide. Animal Data Administration of cyclophosphamide to pregnant mice, rats, rabbits and monkeys during the period of organogenesis at doses at or below the dose in patients based on body surface area resulted in various malformations, which included neural tube defects, limb and digit defects and other skeletal anomalies, cleft lip and palate, and reduced skeletal ossification."],"overdosage":["10 OVERDOSAGE No specific antidote for cyclophosphamide is known. Overdosage should be managed with supportive measures, including appropriate treatment for any concurrent infection, myelosuppression, or cardiac toxicity should it occur. Serious consequences of overdosage include manifestations of dose dependent toxicities such as myelosuppression, urotoxicity, cardiotoxicity (including cardiac failure), veno-occlusive hepatic disease, and stomatitis [see Warnings and Precautions ( 5.1 , 5.2 , 5.3 , and 5.6 )] . Patients who received an overdose should be closely monitored for the development of toxicities, and hematologic toxicity in particular. Cyclophosphamide and its metabolites are dialyzable. Therefore, rapid hemodialysis is indicated when treating any suicidal or accidental overdose or intoxication [ see Clinical Pharmacology ( 12.3 )]. Cystitis prophylaxis with mesna may be helpful in preventing or limiting urotoxic effects with cyclophosphamide overdose."],"references":["15 REFERENCES OSHA Hazardous Drugs. OSHA . ​ http://www.osha.gov/SLTC/hazardousdrugs/index.html ."],"description":["11 DESCRIPTION Cyclophosphamide is an alkylating drug. It is an antineoplastic drug chemically related to the nitrogen mustards. The chemical name for cyclophosphamide is 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate, and has the following structural formula: Cyclophosphamide has a molecular formula of C 7 H 15 Cl 2 N 2 O 2 P•H 2 O and a molecular weight of 279.1. Cyclophosphamide is soluble in water, saline, or ethanol. Cyclophosphamide for Injection, USP is a sterile white cake available as 500 mg, 1 g and 2 g strength single dose vials. 500 mg vial contains 534.5 mg cyclophosphamide monohydrate equivalent to 500 mg cyclophosphamide and 375 mg mannitol 1 g vial contains 1069 mg cyclophosphamide monohydrate equivalent to 1 g cyclophosphamide and 750 mg mannitol 2 g vial contains 2138 mg cyclophosphamide monohydrate equivalent to 2 g cyclophosphamide and 1500 mg mannitol Cyclophosphamide Monohydrate Structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Cyclophosphamide for Injection, USP (lyophilized powder) is a sterile white cake containing cyclophosphamide and mannitol and is supplied in single dose vials. Cyclophosphamide for Injection, USP NDC 39822-0250-1 500 mg per vial, carton of 1 NDC 39822-0255-1 1 g per vial, carton of 1 NDC 39822-0260-1 2 g per vial, carton of 1 Store vials at or below 25°C (77°F). During transport or storage of cyclophosphamide vials, temperature influences can lead to melting of the active ingredient, cyclophosphamide [see Dosage and Administration ( 2.3 )] . Cyclophosphamide is a hazardous product. Follow special handling and disposal procedures. 1"],"geriatric_use":["8.5 Geriatric Use There is insufficient data from clinical studies of cyclophosphamide available for patients 65 years of age and older to determine whether they respond differently than younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac functioning, and of concomitant disease or other drug therapy."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of cyclophosphamide have been established in pediatric patients and information on this use is discussed throughout the labeling. Pre-pubescent females who receive cyclophosphamide generally develop secondary sexual characteristics normally and have regular menses. Ovarian fibrosis with apparently complete loss of germ cells after prolonged administration of cyclophosphamide in late pre-pubescence has been reported. Females who received cyclophosphamide who have retained ovarian function after completing treatment are at increased risk of developing premature menopause. Pre-pubescent males who receive cyclophosphamide develop secondary sexual characteristics normally, but may have oligospermia or azoospermia and increased gonadotropin secretion. Some degree of testicular atrophy may occur. Cyclophosphamide-induced azoospermia is reversible in some patients, though the reversibility may not occur for several years after cessation of therapy."],"effective_time":"20241220","pharmacodynamics":["12.2 Pharmacodynamics Cyclophosphamide exposure-response relationships and the time course of pharmacodynamic response have not been fully characterized."],"pharmacokinetics":["12.3 Pharmacokinetics Cyclophosphamide is a prodrug. Cyclophosphamide pharmacokinetics are linear over the approved recommended dose range. Distribution The volume of distribution of cyclophosphamide is 30 to 50 L. Cyclophosphamide is approximately 20% protein bound, with no dose dependent changes. Some metabolites are greater than 60% protein bound. Elimination The elimination half-life (t½) of cyclophosphamide ranges from 3 to 12 hours, and clearance (CL) ranges from 4 to 5.6 L/h. When cyclophosphamide was administered at 4 g/m 2 (approximately 2 times the approved recommended dosage) over a 90-minute infusion, concentration-time data demonstrate saturable elimination in parallel with first-order renal elimination. Metabolism Cyclophosphamide is metabolized by cytochrome P450s including CYP2A6, 2B6, 3A, 2C9, and 2C19. Cyclophosphamide is activated to form 4-hydroxycyclophosphamide, which is in equilibrium with its ring-open tautomer aldophosphamide. 4-hydroxycyclophosphamide and aldophosphamide can undergo oxidation by aldehyde dehydrogenases to form the inactive metabolites 4-ketocyclophosphamide and carboxyphosphamide, respectively. Aldophosphamide can undergo β-elimination to form active metabolites phosphoramide mustard and acrolein. This spontaneous conversion can be catalyzed by albumin and other proteins. At high doses, the fraction of parent compound cleared by 4-hydroxylation is reduced resulting in non-linear elimination of cyclophosphamide. Cyclophosphamide appears to induce its own metabolism. This auto-induction results in an increase in CL, increased formation of active 4-hydroxycyclophosphamide and shortened t½ following multiple doses administered at 12-to 24-hour interval. Excretion Cyclophosphamide and its metabolites are eliminated by hepatic and renal pathways. Cyclophosphamide is primarily excreted as metabolites. Ten to 20% is excreted unchanged in the urine. A small percentage of cyclophosphamide may be eliminated unchanged in bile. Specific Populations Renal Impairment Following one-hour intravenous infusion, cyclophosphamide AUC increased by 38% in patients with CLcr of 25 to 50 mL/min, by 77% in patients with CLcr of 10 to 24 mL/min and by 23% in the hemodialysis group (CLcr of < 10 mL/min) compared to the control group (CLcr≥ 80 mL/min). Cyclophosphamide is dialyzable. Dialysis clearance averaged 104 mL/min, which is similar to the metabolic clearance of 95 mL/min for cyclophosphamide. A mean of 37% of the administered dose of cyclophosphamide was removed during a 4-hour hemodialysis period. The t½ was 3.3 hours in patients during hemodialysis, a 49% reduction compared to t½ of 6.5 hours in uremic patients. Hepatic Impairment Cyclophosphamide CL is decreased by 40% (45 ± 8.6 L/kg) and t½ is prolonged by 64% (12.5 ± 1 hours) in patients with hepatic impairment with a mean bilirubin 3.5 mg/dL and mean AST 90 IU/L compared to patients with normal hepatic function (mean bilirubin 0.5 mg/dL, mean AST 10 IU/L)."],"adverse_reactions":["6 ADVERSE REACTIONS The following adverse reactions are discussed in more detail in other sections of the labeling. Hypersensitivity [see Contraindications ( 4 )] Myelosuppression, Immunosuppression, Bone Marrow Failure, and Infections [see Warnings and Precautions ( 5.1 )] Urinary Tract and Renal Toxicity [see Warnings and Precautions ( 5.2 )] Cardiotoxicity [see Warnings and Precautions ( 5.3 )] Pulmonary Toxicity [see Warnings and Precautions ( 5.4 )] Secondary Malignancies [see Warnings and Precautions ( 5.5 )] Veno-occlusive Liver Disease [see Warnings and Precautions ( 5.6 )] Infertility [ see Warnings and Precautions ( 5.8 ) and Use in Specific Populations ( 8.3 , 8.4 )] Impaired Wound Healing [see Warnings and Precautions ( 5.9 )] Hyponatremia [see Warnings and Precautions ( 5.10 )] Adverse reactions reported most often include neutropenia, febrile neutropenia, fever, alopecia, nausea, vomiting, and diarrhea. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact XGen Pharmaceuticals DJB, Inc. at 1-866-390-4411 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials and Postmarketing Experience The following adverse reactions associated with the use of cyclophosphamide were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The most common adverse reactions were neutropenia, febrile neutropenia, fever, alopecia, nausea, vomiting, and diarrhea. Cardiac : cardiac arrest, ventricular fibrillation, ventricular tachycardia, cardiogenic shock, pericardial effusion (progressing to cardiac tamponade), myocardial hemorrhage, myocardial infarction, cardiac failure (including fatal outcomes), cardiomyopathy, myocarditis, pericarditis, carditis, atrial fibrillation, supraventricular arrhythmia, ventricular arrhythmia, bradycardia, tachycardia, palpitations, QT prolongation. Congenital, Familial and Genetic: intra-uterine death, fetal malformation, fetal growth retardation, fetal toxicity (including myelosuppression, gastroenteritis). Ear and Labyrinth : deafness, hearing impaired, tinnitus. Endocrine: water intoxication. Eye: visual impairment, conjunctivitis, lacrimation. Gastrointestinal: gastrointestinal hemorrhage, acute pancreatitis, colitis, enteritis, cecitis, stomatitis, constipation, parotid gland inflammation, nausea, vomiting, diarrhea General Disorders and Administrative Site Conditions: multiorgan failure, general physical deterioration, influenza-like illness, injection/infusion site reactions (thrombosis, necrosis, phlebitis, inflammation, pain, swelling, erythema), pyrexia, edema, chest pain, mucosal inflammation, asthenia, pain, chills, fatigue, malaise, headache, febrile neutropenia. Hematologic: myelosuppression, bone marrow failure, disseminated intravascular coagulation and hemolytic uremic syndrome (with thrombotic microangiopathy). Hepatic: veno-occlusive liver disease, cholestatic hepatitis, cytolytic hepatitis, hepatitis, cholestasis; hepatotoxicity with hepatic failure, hepatic encephalopathy, ascites, hepatomegaly, blood bilirubin increased, hepatic function abnormal, hepatic enzymes increased. Immune: immunosuppression, anaphylactic shock and hypersensitivity reaction. Infections : The following manifestations have been associated with myelosuppression and immunosuppression caused by cyclophosphamide: increased risk for and severity of pneumonias (including fatal outcomes), other bacterial, fungal, viral, protozoal and, parasitic infections; reactivation of latent infections, (including viral hepatitis, tuberculosis), Pneumocystis jiroveci , herpes zoster, Strongyloides , sepsis and septic shock. Investigations : blood lactate dehydrogenase increased, C-reactive protein increased. Metabolism and Nutrition: hyponatremia, fluid retention, blood glucose increased, blood glucose decreased. Musculoskeletal and Connective Tissue: rhabdomyolysis, scleroderma, muscle spasms, myalgia, arthralgia. Neoplasms: acute leukemia, myelodysplastic syndrome, lymphoma, sarcomas, renal cell carcinoma, renal pelvis cancer, bladder cancer, ureteric cancer, thyroid cancer. Nervous System : encephalopathy, convulsion, dizziness, neurotoxicity has been reported and manifested as reversible posterior leukoencephalopathy syndrome, myelopathy, peripheral neuropathy, polyneuropathy, neuralgia, dysesthesia, hypoesthesia, paresthesia, tremor, dysgeusia, hypogeusia, parosmia. Pregnancy: premature labor. Psychiatric: confusional state. Renal and Urinary: renal failure, renal tubular disorder, renal impairment, nephropathy toxic, hemorrhagic cystitis, bladder necrosis, cystitis ulcerative, bladder contracture, hematuria, nephrogenic diabetes insipidus, atypical urinary bladder epithelial cells. Reproductive System: infertility, ovarian failure, ovarian disorder, amenorrhea, oligomenorrhea, testicular atrophy, azoospermia, oligospermia. Respiratory: pulmonary veno-occlusive disease, acute respiratory distress syndrome, interstitial lung disease as manifested by respiratory failure (including fatal outcomes), obliterative bronchiolitis, organizing pneumonia, alveolitis allergic, pneumonitis, pulmonary hemorrhage; respiratory distress, pulmonary hypertension, pulmonary edema, pleural effusion, bronchospasm, dyspnea, hypoxia, cough, nasal congestion, nasal discomfort, oropharyngeal pain, rhinorrhea. Skin and Subcutaneous Tissue: toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, palmar-plantar erythrodysesthesia syndrome, radiation recall dermatitis, toxic skin eruption, urticaria, dermatitis, blister, pruritus, erythema, nail disorder, facial swelling, hyperhidrosis, alopecia. Tumor lysis syndrome: like other cytotoxic drugs, cyclophosphamide may induce tumor-lysis syndrome and hyperuricemia in patients with rapidly growing tumors. Vascular: pulmonary embolism, venous thrombosis, vasculitis, peripheral ischemia, hypertension, hypotension, flushing, hot flush."],"contraindications":["4 CONTRAINDICATIONS Hypersensitivity Cyclophosphamide for injection is contraindicated in patients who have a history of severe hypersensitivity reactions to cyclophosphamide, any of its metabolites, or to other components of the product. Anaphylactic reactions including death have been reported with cyclophosphamide. Cross-sensitivity with other alkylating agents can occur. Urinary Outflow Obstruction Cyclophosphamide for injection is contraindicated in patients with urinary outflow obstruction [see Warnings and Precautions ( 5.2 )] . Hypersensitivity to cyclophosphamide ( 4 ) Urinary outflow obstruction ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS 7.1 Effect of Other Drugs on Cyclophosphamide Exposure Protease Inhibitors Concomitant use of protease inhibitors may increase the concentration of cytotoxic metabolites and may enhance the toxicities of cyclophosphamide, including higher incidence of infections, neutropenia, and mucositis. Monitor for increased toxicities in patients receiving protease inhibitors. 7.2 Drugs that Potentiate Cyclophosphamide Toxicities Radiation therapy or drugs with similar toxicities to cyclophosphamide for injection can potentiate toxicities for cyclophosphamide. Monitor for increased toxicities in patients receiving radiation therapy or drugs known to cause: Myelosuppression and/or immunosuppression [ see Warnings and Precautions ( 5.1 )] Nephrotoxicity including hemorrhagic cystitis [see Warnings and Precautions ( 5.2 )] Cardiotoxicity [see Warnings and Precautions ( 5.3 )] Pulmonary toxicity [see Warnings and Precautions ( 5.4 )] Secondary malignancies [see Warnings and Precautions ( 5.5 )] Hepatotoxicity including liver necrosis and VOD [see Warnings and Precautions ( 5.6 )] 7.3 Effect of Cyclophosphamide on Other Drugs Metronidazole Acute encephalopathy has been reported in a patient receiving cyclophosphamide and metronidazole. Monitor for neurologic toxicities in patients receiving metronidazole. Tamoxifen Concomitant use of tamoxifen and a cyclophosphamide-containing chemotherapy regimen may increase the risk of thromboembolic complications. Monitor for signs and symptoms of thromboembolic events in patients receiving tamoxifen. Coumarins Both increased and decreased warfarin effect have been reported in patients receiving warfarin and cyclophosphamide. Monitor anticoagulant activity closely in patients receiving warfarin or other coumarins. Cyclosporine Concomitant administration of cyclophosphamide may decrease serum concentrations of cyclosporine. This interaction may result in an increased incidence of graft-versus-host disease. Monitor for signs and symptoms of graft-versus-host disease in patients receiving cyclosporine. Depolarizing muscle relaxants If a patient has been treated with cyclophosphamide within 10 days of general anesthesia, alert the anesthesiologist. Cyclophosphamide causes a marked and persistent inhibition of cholinesterase activity. Prolonged apnea may occur with concurrent depolarizing muscle relaxants (e.g., succinylcholine)."],"how_supplied_table":["
Cyclophosphamide for Injection, USP
NDC 39822-0250-1500 mg per vial, carton of 1
NDC 39822-0255-11 g per vial, carton of 1
NDC 39822-0260-12 g per vial, carton of 1
"],"mechanism_of_action":["12.1 Mechanism of Action The mechanism of action has not been fully characterized. However, cross-linking of tumor cell DNA may be involved. The active alkylating metabolites of cyclophosphamide interfere with the growth of susceptible rapidly proliferating malignant cells"],"recent_major_changes":["RECENT MAJOR CHANGES Dosage and Administration ( 2.2 , 2.4 ) 9/2024 Warnings and Precautions, Embryo-Fetal Toxicity ( 5.7 ) 9/2024"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The mechanism of action has not been fully characterized. However, cross-linking of tumor cell DNA may be involved. The active alkylating metabolites of cyclophosphamide interfere with the growth of susceptible rapidly proliferating malignant cells 12.2 Pharmacodynamics Cyclophosphamide exposure-response relationships and the time course of pharmacodynamic response have not been fully characterized. 12.3 Pharmacokinetics Cyclophosphamide is a prodrug. Cyclophosphamide pharmacokinetics are linear over the approved recommended dose range. Distribution The volume of distribution of cyclophosphamide is 30 to 50 L. Cyclophosphamide is approximately 20% protein bound, with no dose dependent changes. Some metabolites are greater than 60% protein bound. Elimination The elimination half-life (t½) of cyclophosphamide ranges from 3 to 12 hours, and clearance (CL) ranges from 4 to 5.6 L/h. When cyclophosphamide was administered at 4 g/m 2 (approximately 2 times the approved recommended dosage) over a 90-minute infusion, concentration-time data demonstrate saturable elimination in parallel with first-order renal elimination. Metabolism Cyclophosphamide is metabolized by cytochrome P450s including CYP2A6, 2B6, 3A, 2C9, and 2C19. Cyclophosphamide is activated to form 4-hydroxycyclophosphamide, which is in equilibrium with its ring-open tautomer aldophosphamide. 4-hydroxycyclophosphamide and aldophosphamide can undergo oxidation by aldehyde dehydrogenases to form the inactive metabolites 4-ketocyclophosphamide and carboxyphosphamide, respectively. Aldophosphamide can undergo β-elimination to form active metabolites phosphoramide mustard and acrolein. This spontaneous conversion can be catalyzed by albumin and other proteins. At high doses, the fraction of parent compound cleared by 4-hydroxylation is reduced resulting in non-linear elimination of cyclophosphamide. Cyclophosphamide appears to induce its own metabolism. This auto-induction results in an increase in CL, increased formation of active 4-hydroxycyclophosphamide and shortened t½ following multiple doses administered at 12-to 24-hour interval. Excretion Cyclophosphamide and its metabolites are eliminated by hepatic and renal pathways. Cyclophosphamide is primarily excreted as metabolites. Ten to 20% is excreted unchanged in the urine. A small percentage of cyclophosphamide may be eliminated unchanged in bile. Specific Populations Renal Impairment Following one-hour intravenous infusion, cyclophosphamide AUC increased by 38% in patients with CLcr of 25 to 50 mL/min, by 77% in patients with CLcr of 10 to 24 mL/min and by 23% in the hemodialysis group (CLcr of < 10 mL/min) compared to the control group (CLcr≥ 80 mL/min). Cyclophosphamide is dialyzable. Dialysis clearance averaged 104 mL/min, which is similar to the metabolic clearance of 95 mL/min for cyclophosphamide. A mean of 37% of the administered dose of cyclophosphamide was removed during a 4-hour hemodialysis period. The t½ was 3.3 hours in patients during hemodialysis, a 49% reduction compared to t½ of 6.5 hours in uremic patients. Hepatic Impairment Cyclophosphamide CL is decreased by 40% (45 ± 8.6 L/kg) and t½ is prolonged by 64% (12.5 ± 1 hours) in patients with hepatic impairment with a mean bilirubin 3.5 mg/dL and mean AST 90 IU/L compared to patients with normal hepatic function (mean bilirubin 0.5 mg/dL, mean AST 10 IU/L)."],"indications_and_usage":["1 INDICATIONS AND USAGE Cyclophosphamide for injection is an alkylating drug indicated for treatment of adults and pediatric patients with: Malignant Diseases: malignant lymphomas: Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma ( 1.1 ) Minimal Change Nephrotic Syndrome in Pediatric Patients: biopsy proven minimal change nephrotic syndrome patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy ( 1.2 ) Limitations of Use: The safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established. (1.2) 1.1 Malignant Diseases Cyclophosphamide for injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. 1.2 Minimal Change Nephrotic Syndrome in Pediatric Patients Cyclophosphamide for injection is indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatrics patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy. Limitations of Use: The safety and effectiveness of cyclophosphamide for injection for the treatment of nephrotic syndrome in adults or other renal disease has not been established."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Myelosuppression, Immunosuppression, Bone Marrow Failure and Infections: Severe immunosuppression may lead to serious and sometimes fatal infections. Close hematological monitoring is required. ( 5.1 ) Urinary Tract and Renal Toxicity: Hemorrhagic cystitis, pyelitis, ureteritis, and hematuria can occur. Urotoxicity can be fatal. Exclude or correct any urinary tract obstructions prior to treatment. ( 5.2 ) Cardiotoxicity: Myocarditis, myopericarditis, pericardial effusion, arrythmias and congestive heart failure, which may be fatal, have been reported. Monitor patients, especially those with risk factors for cardiotoxicity or pre-existing cardiac disease. ( 5.3 ) Pulmonary Toxicity: Pneumonitis, pulmonary fibrosis and pulmonary veno-occlusive disease leading to respiratory failure may occur. Monitor patients for signs and symptoms of pulmonary toxicity. ( 5.4 ) Secondary malignancies ( 5.5 ) Veno-occlusive Liver Disease: Fatal outcome can occur. ( 5.6 ) Embryo-Fetal Toxicity: Can cause fetal harm. Advise patients of reproductive potential of the portential risk to a fetus and to use effective contraception. ( 5.7 , 8.1 , 8.3 ) 5.1 Myelosuppression, Immunosuppression, Bone Marrow Failure and Infections Cyclophosphamide can cause myelosuppression (leukopenia, neutropenia, thrombocytopenia and anemia), bone marrow failure, and severe immunosuppression which may lead to serious and sometimes fatal infections, including sepsis and septic shock. Latent infections can be reactivated [see Adverse Reactions ( 6.2 )] . Antimicrobial prophylaxis may be indicated in certain cases of neutropenia at the discretion of the managing physician. In case of neutropenic fever, antibiotic therapy is indicated. Antimycotics and/or antivirals may also be indicated. Monitoring of complete blood counts is essential during cyclophosphamide treatment so that the dose can be adjusted, if needed. Cyclophosphamide should not be administered to patients with neutrophils ≤1,500/mm 3 and platelets < 50,000/mm 3 . Cyclophosphamide treatment may not be indicated, or should be interrupted, or the dose reduced, in patients who have or who develop a serious infection. G-CSF may be administered to reduce the risks of neutropenia complications associated with cyclophosphamide use. Primary and secondary prophylaxis with G-CSF should be considered in all patients considered to be at increased risk for neutropenia complications. The nadirs of the reduction in leukocyte count and thrombocyte count are usually reached in weeks 1 and 2 of treatment. Peripheral blood cell counts are expected to normalize after approximately 20 days. Bone marrow failure has been reported. Severe myelosuppression may be expected particularly in patients pretreated with and/or receiving concomitant chemotherapy and/or radiation therapy. 5.2 Urinary Tract and Renal Toxicity Hemorrhagic cystitis, pyelitis, ureteritis, and hematuria have been reported with cyclophosphamide. Medical and/or surgical supportive treatment may be required to treat protracted cases of severe hemorrhagic cystitis. Discontinue cyclophosphamide therapy in case of severe hemorrhagic cystitis. Urotoxicity (bladder ulceration, necrosis, fibrosis, contracture and secondary cancer) may require interruption of cyclophosphamide treatment or cystectomy. Urotoxicity can be fatal. Urotoxicity can occur with short-term or long-term use of cyclophosphamide. Before starting treatment, exclude or correct any urinary tract obstructions [see Contraindications ( 4 )] . Urinary sediment should be checked regularly for the presence of erythrocytes and other signs of urotoxicity and/or nephrotoxicity. Cyclophosphamide should be used with caution, if at all, in patients with active urinary tract infections. Aggressive hydration with forced diuresis and frequent bladder emptying can reduce the frequency and severity of bladder toxicity. Mesna has been used to prevent severe bladder toxicity. 5.3 Cardiotoxicity Myocarditis, myopericarditis, pericardial effusion including cardiac tamponade, and congestive heart failure, which may be fatal, have been reported with cyclophosphamide therapy. Supraventricular arrhythmias (including atrial fibrillation and flutter) and ventricular arrhythmias (including severe QT prolongation associated with ventricular tachyarrhythmia) have been reported after treatment with regimens that included cyclophosphamide. The risk of cardiotoxicity may be increased with high doses of cyclophosphamide, in patients with advanced age, and in patients with previous radiation treatment to the cardiac region and/or previous or concomitant treatment with other cardiotoxic agents. Particular caution is necessary in patients with risk factors for cardiotoxicity and in patients with pre-existing cardiac disease. Monitor patients with risk factors for cardiotoxicity and with pre-existing cardiac disease. 5.4 Pulmonary Toxicity Pneumonitis, pulmonary fibrosis, pulmonary veno-occlusive disease and other forms of pulmonary toxicity leading to respiratory failure have been reported during and following treatment with cyclophosphamide. Late onset pneumonitis (greater than 6 months after start of cyclophosphamide) appears to be associated with increased mortality. Pneumonitis may develop years after treatment with cyclophosphamide. Monitor patients for signs and symptoms of pulmonary toxicity. 5.5 Secondary Malignancies Cyclophosphamide is genotoxic [see Nonclinical Toxicology ( 13.1 )] . Secondary malignancies (urinary tract cancer, myelodysplasia, acute leukemias, lymphomas, thyroid cancer, and sarcomas) have been reported in patients treated with cyclophosphamide-containing regimens . The risk of bladder cancer may be reduced by prevention of hemorrhagic cystitis. 5.6 Veno-occlusive Liver Disease Veno-occlusive liver disease (VOD) including fatal outcome has been reported in patients receiving cyclophosphamide-containing regimens. A cytoreductive regimen in preparation for bone marrow transplantation that consists of cyclophosphamide in combination with whole-body irradiation, busulfan, or other agents has been identified as a major risk factor. VOD has also been reported to develop gradually in patients receiving long-term low-dose immunosuppressive doses of cyclophosphamide. Other risk factors predisposing to the development of VOD include preexisting disturbances of hepatic function, previous radiation therapy of the abdomen, and a low performance status. 5.7 Embryo-Fetal Toxicity Based on its mechanism of action and published reports of effects in pregnant patients or animals, cyclophosphamide for injection can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations ( 8.1 ), Clinical Pharmacology ( 12.1 ), and Nonclinical Toxicology ( 13.1 )] . Exposure to cyclophosphamide during pregnancy may cause birth defects, miscarriage, fetal growth retardation, and fetotoxic effects in the newborn. Cyclophosphamide is teratogenic and embryo-fetal toxic in mice, rats, rabbits and monkeys. Advise pregnant women and females of reproductive potential of the potential risk to a fetus [see Use in Specific Populations ( 8.1 )] . Advise females of reproductive potential to use effective contraception during treatment with cyclophosphamide for injection and for up to 1 year after completion of therapy. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with cyclophosphamide for injection and for 4 months after completion of therapy [see Use in Specific Populations ( 8.1 , 8.3 )] . 5.8 Infertility Male and female reproductive function and fertility may be impaired in patients being treated with cyclophosphamide for injection. Cyclophosphamide interferes with oogenesis and spermatogenesis. It may cause sterility in both sexes. Development of sterility appears to depend on the dose of cyclophosphamide, duration of therapy, and the state of gonadal function at the time of treatment. Cyclophosphamide-induced sterility may be irreversible in some patients. Advise patients on the potential risks for infertility [see Use in Specific Populations ( 8.3 and 8.4 )] . 5.9 Impairment of Wound Healing Cyclophosphamide may interfere with normal wound healing. 5.10 Hyponatremia Hyponatremia associated with increased total body water, acute water intoxication, and a syndrome resembling SIADH (syndrome of inappropriate secretion of antidiuretic hormone), which may be fatal, has been reported."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Cyclophosphamide administered by different routes, including intravenous, subcutaneous or intraperitoneal injection, or in drinking water, caused tumors in both mice and rats. In addition to leukemia and lymphoma, benign and malignant tumors were found at various tissue sites, including urinary bladder, mammary gland, lung, liver, and injection site [see Warnings and Precautions ( 5.5 )] . Cyclophosphamide was mutagenic and clastogenic in multiple in vitro and in vivo genetic toxicology studies. Cyclophosphamide is genotoxic in male and female germ cells. Animal data indicate that exposure of oocytes to cyclophosphamide during follicular development may result in a decreased rate of implantations and viable pregnancies, and in an increased risk of malformations. Male mice and rats treated with cyclophosphamide show alterations in male reproductive organs (e.g., decreased weights, atrophy, changes in spermatogenesis), and decreases in reproductive potential (e.g., decreased implantations and increased post-implantation loss) and increases in fetal malformations when mated with untreated females [see Use in Specific Populations ( 8.3 )] ."],"spl_unclassified_section":["17 PATIENT COUNSELING INFORMATION Advise the patient of the following: Myelosuppression, Immunosuppression and Infections Inform patients of the possibility of myelosuppression, immunosuppression, and infections (sometimes fatal). Explain the need for routine blood cell counts. Instruct patients to monitor their temperature frequently and immediately report any occurrence of fever [see Warnings and Precautions ( 5.1 )] . Urinary Tract and Renal Toxicity Advise the patient to report urinary symptoms (patients should report if their urine has turned a pink or red color) and the need for increasing fluid intake and frequent voiding [see Warnings and Precautions ( 5.2 )] . Cardiotoxicity Inform patients of the possibility of cardiotoxicity (which may be fatal). Advise patients to contact a health care professional immediately for any of the following: new onset or worsening shortness of breath, cough, swelling of the ankles/legs, palpitations, weight gain of more than 5 pounds in 24 hours, dizziness or loss of consciousness [see Warnings and Precautions ( 5.3 ]. Pulmonary Toxicity Warn patients of the possibility of developing non-infectious pneumonitis. Advise patients to report promptly any new or worsening respiratory symptoms [see Warnings and Precautions ( 5.4 )]. Secondary Malignancies Inform patients that there is an increased risk of secondary malignancies with cyclophosphamide for injection [ see Warnings and Precautions ( 5.5 )]. Embryo-Fetal Toxicity Inform female patients of the risk to a fetus and potential loss of the pregnancy. Advise females to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 )] Advise female patients of reproductive potential to use effective contraception during treatment and for up to 1 year after completion of therapy [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 , 8.3 )]. Advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 4 months after completion of therapy. [see Warnings and Precautions ( 5.7 ) and Use in Specific Populations ( 8.1 , 8.3 )]. Lactation Advise lactating women not to breastfeed during treatment and for 1 week after the last dose of cyclophosphamide for injection [ see Use in Specific Populations ( 8.2 )]. Infertility Advise males and females of reproductive potential that cyclophosphamide for injection may impair fertility [see Warnings and Precautions ( 5.8 ) and Use in Specific Populations ( 8.3 , 8.4 )] Common Adverse Reactions Explain to patients that side effects such as nausea, vomiting, stomatitis, impaired wound healing, amenorrhea, premature menopause, sterility and hair loss may be associated with cyclophosphamide administration. Other undesirable effects (including, e.g., dizziness, blurred vision, visual impairment) could affect the ability to drive or use machines [see Adverse Reactions ( 6.1 , 6.2)]. Hydration and Important Administration Instructions Advise the patients that during or immediately after the administration, adequate amounts of fluid are required to reduce the risk of urinary tract toxicity [see Dosage and Administration ( 2.1 )].","Made in Argentina. Manufactured for: XGen Pharmaceuticals DJB, Inc. Big Flats, NY 14814 Revised: September 2024 CY-PI-02 MST-PR-4246-02"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION During or immediately after cyclophosphamide for injection administration, administer adequate amounts of fluid to reduce the risk of urinary tract toxicity ( 2.1 ). Malignant Diseases: Adult and Pediatric Patients ( 2.2 ) Intravenous: Initial course for patients with no hematologic deficiency: 40 mg per kg to 50 mg per kg in divided doses over 2 to 5 days. Other regimens include 10 mg per kg to 15 mg per kg given every 7 to 10 days or 3 mg per kg to 5 mg per kg twice weekly. Oral: 1 mg per kg per day to 5 mg per kg per day for both initial and maintenance dosing. Minimal Change Nephrotic Syndrome in Pediatric Patients ( 2.3 ) Oral: 2 mg per kg daily for 8 to 12 weeks (maximum cumulative dose 168 mg per kg). Treatment beyond 90 days increases the probability of sterility in males. ( 8.4 ) 2.1 Important Administration Instructions During or immediately after the administration of cyclophosphamide for injection, adequate amounts of fluid should be ingested or infused to force diuresis in order to reduce the risk of urinary tract toxicity. Therefore, cyclophosphamide for injection should be administered in the morning. 2.2 Recommended Dosage for Malignant Diseases Adults and Pediatric Patients Intravenous Use When used as the only oncolytic drug therapy, the recommended dosage for the initial course of cyclophosphamide for injection for patients with no hematologic deficiency is 40 mg per kg to 50 mg per kg given intravenously in divided doses over a period of 2 to 5 days. Other intravenous regimens include 10 mg per kg to 15 mg per kg given every 7 to 10 days or 3 mg per kg to 5 mg per kg twice weekly. Oral Use The recommended dosage for oral cyclophosphamide is 1 mg per kg per day to 5 mg per kg per day for both initial and maintenance dosing. Adjust the dosage of cyclophosphamide for injection based on the specific regimen administered, response to treatment, myelosuppression or other adverse reactions, and patient risk factors [see Warning and Precautions (5)]. 2.3 Recommended Dosage for Minimal Change Nephrotic Syndrome in Pediatric Patients The recommended dosage is 2 mg per kg orally once daily for 8 to 12 weeks (maximum cumulative dose 168 mg per kg) is recommended. Treatment beyond 90 days increases the probability of sterility in males [see Use in Specific Populations ( 8.4 )] . 2.4 Preparation, Handling and Administration Cyclophosphamide for injection is a hazardous drug. Follow applicable special handling and disposal procedures. 1 Caution should be exercised when handling and preparing cyclophosphamide for injection. To minimize the risk of dermal exposure, always wear gloves when handling vials containing cyclophosphamide for injection. Cyclophosphamide for Injection Intravenous Administration Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use cyclophosphamide vials if there are signs of melting. Melted cyclophosphamide is a clear or yellowish viscous liquid usually found as a connected phase or in droplets in the affected vials. Cyclophosphamide for injection does not contain any antimicrobial preservative and thus care must be taken to assure the sterility of prepared solutions. Use aseptic technique. For Direct Intravenous Injection Reconstitute cyclophosphamide for injection with 0.9% Sodium Chloride Injection, USP only, using the volumes listed below in Table 1. Shake the vial vigorously to dissolve the drug completely. Do not use Sterile Water for Injection, USP because it results in a hypotonic solution and should not be injected directly. Discard unused solution. Table 1: Reconstitution for Direct Intravenous Injection Strength Volume of 0.9% Sodium Chloride Injection, USP Cyclophosphamide Concentration 500 mg 25 mL 20 mg per mL 1 g 50 mL 2 g 100 mL For Intravenous Infusion Reconstitution of Cyclophosphamide for Injection: Reconstitute cyclophosphamide for injection using 0.9% Sodium Chloride Injection, USP or Sterile Water for Injection, USP with the volume of diluent listed below in Table 2. Add the diluent to the vial and shake the vial vigorously to dissolve the drug completely. Discard unused solution. Table 2: Reconstitution in preparation for Intravenous Infusion Strength Volume of Diluent Cyclophosphamide Concentration 500 mg 25 mL 20 mg per mL 1 g 50 mL 2 g 100 mL Dilution of Reconstituted Cyclophosphamide for Injection: Further dilute the reconstituted cyclophosphamide for injection solution to a minimum concentration of 2 mg per mL with any of the following diluents: 0.45% Sodium Chloride Injection, USP 5% Dextrose Injection, USP 5% Dextrose and 0.9% Sodium Chloride Injection, USP To reduce the likelihood of adverse reactions that appear to be administration rate-dependent (e.g., facial swelling, headache, nasal congestion, scalp burning), cyclophosphamide should be injected or infused very slowly. Duration of the infusion also should be appropriate for the volume and type of carrier fluid to be infused. Storage of Reconstituted and Diluted Cyclophosphamide Solution: If not used immediately, for microbiological integrity, cyclophosphamide solutions should be stored as described in Table 3: Table 3: Storage of Cyclophosphamide Solutions Diluent Storage Room Temperature Refrigerated Reconstituted Solution (Without Further Dilution) 0.9% Sodium Chloride Injection, USP up to 24 hrs Up to 6 days Sterile Water for Injection, USP Do not store; use immediately Diluted Solutions 1 0.45% Sodium Chloride Injection, USP up to 24 hrs up to 6 days 5% Dextrose Injection, USP up to 24 hrs up to 36 hrs 5% Dextrose and 0.9% Sodium Chloride Injection, USP up to 24 hrs up to 36 hrs 1 Storage time is the total time cyclophosphamide is in solution including the time it is reconstituted in 0.9% Sterile Sodium Chloride Injection, USP or Sterile Water for Injection, USP. Reconstituted Solution for Oral Administration Liquid preparations of cyclophosphamide for oral administration may be prepared by dissolving cyclophosphamide for injection in Aromatic Elixir, National Formulary (NF). Store preparations under refrigeration in glass containers and used within 14 days. See the prescribing information for cyclophosphamide for oral use for additional dosage information."],"spl_product_data_elements":["CYCLOPHOSPHAMIDE Cyclophosphamide MANNITOL CYCLOPHOSPHAMIDE 4-HYDROXYCYCLOPHOSPHAMIDE CYCLOPHOSPHAMIDE ANHYDROUS CYCLOPHOSPHAMIDE Cyclophosphamide MANNITOL CYCLOPHOSPHAMIDE 4-HYDROXYCYCLOPHOSPHAMIDE CYCLOPHOSPHAMIDE ANHYDROUS CYCLOPHOSPHAMIDE Cyclophosphamide MANNITOL CYCLOPHOSPHAMIDE 4-HYDROXYCYCLOPHOSPHAMIDE CYCLOPHOSPHAMIDE ANHYDROUS"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Cyclophosphamide for injection (lyophilized powder) is a sterile white cake available in single does vials. 500 mg 1 g 2 g For Injection, lyophilized powder: 500 mg, 1 g and 2 g ( 3 )"],"recent_major_changes_table":["
Dosage and Administration ( 2.2, 2.4) 9/2024
Warnings and Precautions, Embryo-Fetal Toxicity ( 5.7) 9/2024
"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Lactation: Advise not to breastfeed. ( 8.2 ) Renal Impairment: Monitor for toxicity in patients with moderate and severe renal impairment. ( 8.6 , 12.3 ) See 17 for PATIENT COUNSELING INFORMATION 8.1 Pregnancy Risk Summary Based on its mechanism of action and published reports of effects in pregnant patients or animals, cyclophosphamide for injection can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology ( 12.1 ) and Nonclinical Toxicology ( 13.1 )]. Exposure to cyclophosphamide during pregnancy may cause fetal malformations, miscarriage, fetal growth retardation, and toxic effects in the newborn [see Data] . Cyclophosphamide is teratogenic and embryo-fetal toxic in mice, rats, rabbits and monkeys [see Data] . Advise pregnant women and females of reproductive potential of the potential risk to the fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects is 2%-4% and miscarriage is 15%-20% of clinically recognized pregnancies. Data Human Data Malformations of the skeleton, palate, limbs and eyes as well as miscarriage have been reported after exposure to cyclophosphamide in the first trimester. Fetal growth retardation and toxic effects manifesting in the newborn, including leukopenia, anemia, pancytopenia, severe bone marrow hypoplasia, and gastroenteritis have been reported after exposure to cyclophosphamide. Animal Data Administration of cyclophosphamide to pregnant mice, rats, rabbits and monkeys during the period of organogenesis at doses at or below the dose in patients based on body surface area resulted in various malformations, which included neural tube defects, limb and digit defects and other skeletal anomalies, cleft lip and palate, and reduced skeletal ossification. 8.2 Lactation Risk summary Cyclophosphamide is present in breast milk. Neutropenia, thrombocytopenia, low hemoglobin, and diarrhea have been reported in infants breast fed by women treated with cyclophosphamide. Because of the potential for serious adverse reactions in a breastfed child, advise lactating women not to breastfeed during treatment with cyclophosphamide for injection and for 1 week after the last dose. 8.3 Females and Males of Reproductive Potential Cyclophosphamide for injection can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations ( 8.1 )]. Pregnancy Testing Verify the pregnancy status of females of reproductive potential prior to the initiation of cyclophosphamide for injection. Contraception Females Advise females of reproductive potential to use effective contraception during treatment with cyclophosphamide for injection and for up to 1 year after completion of therapy. Males Based on findings in genetic toxicity and animal reproduction studies, advise male patients with female partners of reproductive potential to use effective contraception during treatment with cyclophosphamide for injection and for 4 months after completion of therapy [see Nonclinical Toxicology ( 13.1 ) ]. Infertility Females Amenorrhea, transient or permanent, associated with decreased estrogen and increased gonadotropin secretion develops in a proportion of women treated with cyclophosphamide. Affected patients generally resume regular menses within a few months after cessation of therapy. The risk of premature menopause with cyclophosphamide increases with age. Oligomenorrhea has also been reported in association with cyclophosphamide treatment. Animal data suggest an increased risk of failed pregnancy and malformations may persist after discontinuation of cyclophosphamide as long as oocytes/follicles exist that were exposed to cyclophosphamide during any of their maturation phases. The exact duration of follicular development in humans is not known, but may be longer than 12 months [see Nonclinical Toxicology ( 13.1 )]. Males Men treated with cyclophosphamide may develop oligospermia or azoospermia which are normally associated with increased gonadotropin but normal testosterone secretion. 8.4 Pediatric Use The safety and effectiveness of cyclophosphamide have been established in pediatric patients and information on this use is discussed throughout the labeling. Pre-pubescent females who receive cyclophosphamide generally develop secondary sexual characteristics normally and have regular menses. Ovarian fibrosis with apparently complete loss of germ cells after prolonged administration of cyclophosphamide in late pre-pubescence has been reported. Females who received cyclophosphamide who have retained ovarian function after completing treatment are at increased risk of developing premature menopause. Pre-pubescent males who receive cyclophosphamide develop secondary sexual characteristics normally, but may have oligospermia or azoospermia and increased gonadotropin secretion. Some degree of testicular atrophy may occur. Cyclophosphamide-induced azoospermia is reversible in some patients, though the reversibility may not occur for several years after cessation of therapy. 8.5 Geriatric Use There is insufficient data from clinical studies of cyclophosphamide available for patients 65 years of age and older to determine whether they respond differently than younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac functioning, and of concomitant disease or other drug therapy. 8.6 Renal Impairment In patients with severe renal impairment, decreased renal excretion may result in increased plasma levels of cyclophosphamide and its metabolites, which may increase toxicity [see Clinical Pharmacology ( 12.3 ) ]. Monitor patients with severe renal impairment (creatinine clearance (CLcr) =10 mL/min to 24 mL/min) for signs and symptoms of toxicity. Cyclophosphamide and its metabolites are dialyzable although there are probably quantitative differences depending upon the dialysis system. In patients requiring dialysis, consider using a consistent interval between cyclophosphamide administration and dialysis. 8.7 Hepatic Impairment Patients with severe hepatic impairment have reduced conversion of cyclophosphamide to the active 4-hydroxyl metabolite, potentially reducing efficacy [see Clinical Pharmacology ( 12.3 )] . Monitor patients with severe hepatic impairment (total bilirubin > 3 x ULN and any aspartate aminotransferase (AST)) for reduced effectiveness of cyclophosphamide."],"dosage_and_administration_table":["
Table 1: Reconstitution for Direct Intravenous Injection
StrengthVolume of 0.9% Sodium Chloride Injection, USPCyclophosphamide Concentration
500 mg25 mL20 mg per mL
1 g50 mL
2 g100 mL
","
Table 2: Reconstitution in preparation for Intravenous Infusion
StrengthVolume of DiluentCyclophosphamide Concentration
500 mg25 mL20 mg per mL
1 g50 mL
2 g100 mL
","
Table 3: Storage of Cyclophosphamide Solutions
DiluentStorage
Room TemperatureRefrigerated
Reconstituted Solution (Without Further Dilution)
0.9% Sodium Chloride Injection, USPup to 24 hrsUp to 6 days
Sterile Water for Injection, USPDo not store; use immediately
Diluted Solutions 1
0.45% Sodium Chloride Injection, USPup to 24 hrsup to 6 days
5% Dextrose Injection, USPup to 24 hrsup to 36 hrs
5% Dextrose and 0.9% Sodium Chloride Injection, USPup to 24 hrsup to 36 hrs
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 1 g Carton and Vial NDC 39822-0255-1 Cyclophosphamide for Injection, USP 1 g/vial Lyophilized CYTOTOXIC AGENT After Reconstitution: For direct intravenous injection or must be further diluted before intravenous infusion Single-dose vial. Discard unused solution. Rx Only 1 gran carton 1 g vial","PRINCIPAL DISPLAY PANEL - 2 g Carton and Vial NDC 39822-0260-1 Cyclophosphamide for Injection, USP 2 g/vial Lyophilized CYTOTOXIC AGENT After Reconstitution: For direct intravenous injection or must be further diluted before intravenous infusion Single-dose vial. Discard unused solution. Rx Only 2 g carton 2g vial","PRINCIPAL DISPLAY PANEL - 500 mg Carton and Vial NDC 39822-0250-1 Single-dose vial. Discard unused solution. Cyclophosphamide for Injection, USP 500 mg/vial Lyophilized CYTOTOXIC AGENT After Reconstitution: For direct intravenous injection or must be further diluted before intravenous infusion Rx Only 500 mg carton 500 mg vial"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Cyclophosphamide administered by different routes, including intravenous, subcutaneous or intraperitoneal injection, or in drinking water, caused tumors in both mice and rats. In addition to leukemia and lymphoma, benign and malignant tumors were found at various tissue sites, including urinary bladder, mammary gland, lung, liver, and injection site [see Warnings and Precautions ( 5.5 )] . Cyclophosphamide was mutagenic and clastogenic in multiple in vitro and in vivo genetic toxicology studies. Cyclophosphamide is genotoxic in male and female germ cells. Animal data indicate that exposure of oocytes to cyclophosphamide during follicular development may result in a decreased rate of implantations and viable pregnancies, and in an increased risk of malformations. Male mice and rats treated with cyclophosphamide show alterations in male reproductive organs (e.g., decreased weights, atrophy, changes in spermatogenesis), and decreases in reproductive potential (e.g., decreased implantations and increased post-implantation loss) and increases in fetal malformations when mated with untreated females [see Use in Specific Populations ( 8.3 )] ."]},"tags":[{"label":"cyclophosphamide","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Cytochrome P450 3A4","category":"target"},{"label":"CYP3A4","category":"gene"},{"label":"L01AA01","category":"atc"},{"label":"Oral","category":"route"},{"label":"Intravenous","category":"route"},{"label":"Capsule","category":"form"},{"label":"Injection","category":"form"},{"label":"Tablet","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Established","category":"status"},{"label":"Acute lymphoid leukemia, disease","category":"indication"},{"label":"Acute monocytic leukemia","category":"indication"},{"label":"Acute myelogenous leukemia","category":"indication"},{"label":"Adenocarcinoma of the ovary","category":"indication"},{"label":"Burkitt's lymphoma","category":"indication"},{"label":"Carcinoma of breast","category":"indication"},{"label":"Baxter Hlthcare","category":"company"},{"label":"Approved 1950s","category":"decade"},{"label":"Alkylating Agents","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Antineoplastic Agents, Alkylating","category":"pharmacology"},{"label":"Antirheumatic Agents","category":"pharmacology"},{"label":"Immunologic Factors","category":"pharmacology"},{"label":"Immunosuppressive Agents","category":"pharmacology"},{"label":"Mutagens","category":"pharmacology"},{"label":"Myeloablative Agonists","category":"pharmacology"},{"label":"Noxae","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":14305.334,"date":"","count":10822,"signal":"Febrile neutropenia","source":"DrugCentral FAERS","actionTaken":"Reported 10,822 times (LLR=14305)"},{"llr":6469.175,"date":"","count":7949,"signal":"Neutropenia","source":"DrugCentral FAERS","actionTaken":"Reported 7,949 times (LLR=6469)"},{"llr":4019.848,"date":"","count":5246,"signal":"Disease progression","source":"DrugCentral FAERS","actionTaken":"Reported 5,246 times (LLR=4020)"},{"llr":3357.888,"date":"","count":2238,"signal":"Myelosuppression","source":"DrugCentral FAERS","actionTaken":"Reported 2,238 times (LLR=3358)"},{"llr":3173.074,"date":"","count":2022,"signal":"Cytokine release syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 2,022 times (LLR=3173)"},{"llr":2867.171,"date":"","count":5212,"signal":"Product use in unapproved indication","source":"DrugCentral FAERS","actionTaken":"Reported 5,212 times (LLR=2867)"},{"llr":2620.262,"date":"","count":2182,"signal":"Bone marrow failure","source":"DrugCentral FAERS","actionTaken":"Reported 2,182 times (LLR=2620)"},{"llr":2607.765,"date":"","count":2602,"signal":"Mucosal inflammation","source":"DrugCentral FAERS","actionTaken":"Reported 2,602 times (LLR=2608)"},{"llr":2593.043,"date":"","count":1802,"signal":"Myelodysplastic syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 1,802 times (LLR=2593)"},{"llr":2562.832,"date":"","count":1786,"signal":"Acute myeloid leukaemia","source":"DrugCentral FAERS","actionTaken":"Reported 1,786 times (LLR=2563)"},{"llr":2336.093,"date":"","count":4746,"signal":"Thrombocytopenia","source":"DrugCentral FAERS","actionTaken":"Reported 4,746 times (LLR=2336)"},{"llr":2292.142,"date":"","count":1342,"signal":"Haematotoxicity","source":"DrugCentral FAERS","actionTaken":"Reported 1,342 times (LLR=2292)"},{"llr":2248.612,"date":"","count":1074,"signal":"Cystitis haemorrhagic","source":"DrugCentral FAERS","actionTaken":"Reported 1,074 times (LLR=2249)"},{"llr":2206.383,"date":"","count":1852,"signal":"Cytomegalovirus infection","source":"DrugCentral FAERS","actionTaken":"Reported 1,852 times (LLR=2206)"},{"llr":2200.628,"date":"","count":1135,"signal":"Acute graft versus host disease","source":"DrugCentral FAERS","actionTaken":"Reported 1,135 times (LLR=2201)"}],"drugInteractions":[{"url":"/drug/fluconazole","drug":"fluconazole","action":"Monitor closely","effect":"May interact with Fluconazole","source":"DrugCentral","drugSlug":"fluconazole"},{"url":"/drug/itraconazole","drug":"itraconazole","action":"Monitor closely","effect":"May interact with Itraconazole","source":"DrugCentral","drugSlug":"itraconazole"}],"commonSideEffects":[{"effect":"Nausea and vomiting","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Leukopenia","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Alopecia","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Anorexia","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Abdominal discomfort or pain","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Diarrhea","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Thrombocytopenia or anemia","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Hemorrhagic colitis","drugRate":"isolated reports","severity":"serious"},{"effect":"Oral mucosal ulceration","drugRate":"isolated reports","severity":"serious"},{"effect":"Jaundice","drugRate":"isolated reports","severity":"serious"},{"effect":"Skin rash","drugRate":"occasionally","severity":"mild"},{"effect":"Pigmentation of the skin","drugRate":"occasionally","severity":"mild"},{"effect":"Changes in nails","drugRate":"occasionally","severity":"mild"},{"effect":"Stevens-Johnson syndrome","drugRate":"very rare","severity":"mild"},{"effect":"Toxic epidermal necrolysis","drugRate":"very rare","severity":"mild"},{"effect":"Interstitial pneumonitis","drugRate":"reported","severity":"mild"},{"effect":"Interstitial pulmonary fibrosis","drugRate":"reported","severity":"mild"},{"effect":"Hemorrhagic ureteritis","drugRate":"reported","severity":"mild"},{"effect":"Renal tubular necrosis","drugRate":"reported","severity":"mild"},{"effect":"Fever without documented infection","drugRate":"reported","severity":"mild"},{"effect":"Malaise","drugRate":"reported","severity":"mild"},{"effect":"Asthenia","drugRate":"reported","severity":"mild"},{"effect":"SIADH (syndrome of inappropriate ADH secretion)","drugRate":"reported","severity":"mild"},{"effect":"Anaphylactic reactions","drugRate":"reported","severity":"mild"},{"effect":"Carcinogenesis","drugRate":"reported","severity":"mild"},{"effect":"Mutagenesis","drugRate":"reported","severity":"mild"},{"effect":"Impairment of Fertility","drugRate":"reported","severity":"mild"}],"contraindications":["Blood dyscrasias"],"specialPopulations":{"Pregnancy":"Cyclophosphamide can cause fetal harm when administered to pregnant woman based on its mechanism of action and published reports of effects in pregnant patients or animals. Exposure to cyclophosphamide during pregnancy may cause fetal malformations, miscarriage, fetal growth retardation, and toxic effects in the newborn. Cyclophosphamide is teratogenic and embryo-fetal toxic in mice, rats, rabbits and monkeys. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, apprise the patient of the potential hazard to fetus. Human DataMalformations of the skeleton, palate, limbs and eyes as well as miscarriage have been reported after exposure to cyclophosphamide in the first trimester. Fetal growth retardation and toxic effects manifesting in the newborn, including leukopenia, anemia, pancytopenia, severe bone marrow hypoplasia, and gastroent","Geriatric use":"Insufficient data from clinical studies of cyclophosphamide for malignant lymphoma, multiple myeloma, leukemia, mycosis fungoides, neuroblastoma, retinoblastoma, and breast carcinoma are available for patients 65 years of age and older to determine whether they respond differently than younger patients. In two clinical trials in which cyclophosphamide was compared with paclitaxel, each in combination with cisplatin, for the treatment of advanced ovarian carcinoma, 154 (28%) of 552 ","Paediatric use":"The safety profile of cyclophosphamide in pediatric patients is similar to that of the adult population (see ADVERSE REACTIONS).","Renal impairment":"Monitor for toxicity in patients with moderate and severe renal impairment."}},"trials":[],"aliases":[],"company":"Baxter","patents":[{"type":"Formulation","number":"12329767","applicant":"DR REDDYS LABORATORIES INC","territory":"US","tradeName":"CYCLOPHOSPHAMIDE","expiryDate":"2036-02-15"},{"type":"Formulation","number":"10993952","applicant":"DR REDDYS LABORATORIES INC","territory":"US","tradeName":"CYCLOPHOSPHAMIDE","expiryDate":"2036-02-15"},{"type":"Formulation","number":"9662342","applicant":"EUGIA PHARMA SPECIALITIES LTD","territory":"US","tradeName":"CYCLOPHOSPHAMIDE","expiryDate":"2035-06-26"},{"type":"Formulation","number":"10849916","applicant":"AVYXA HOLDINGS LLC","territory":"US","tradeName":"FRINDOVYX","expiryDate":"2035-07-13"},{"type":"Formulation","number":"11382923","applicant":"AVYXA HOLDINGS LLC","territory":"US","tradeName":"FRINDOVYX","expiryDate":"2035-12-01"}],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$4.0710/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$1,486","description":"CYCLOPHOSPHAMIDE 50 MG CAPSULE","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CYCLOPHOSPHAMIDE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T05:57:00.856463+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T05:57:00.856375+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T05:57:06.187188+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CYCLOPHOSPHAMIDE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T05:57:06.504343+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:56:59.754331+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:56:59.754355+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: DNA inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:57:07.559491+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1200796/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T05:57:07.223213+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA211757","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T05:56:59.754359+00:00"}},"allNames":"cytoxan (lyophilized)","offLabel":[],"synonyms":["cyclophosphamide","cyclophosphamid","cyclophosphamidum","cyclophosphan","cyclophosphane","cytophosphan","mitoxan","cyclophosphamide hydrate","endoxan"],"timeline":[{"date":"1959-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from BAXTER HLTHCARE to Baxter Hlthcare"},{"date":"1959-11-16","type":"positive","source":"DrugCentral","milestone":"FDA approval (Baxter Hlthcare)"},{"date":"1993-04-29","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 3 manufacturers approved"},{"date":"2013-09-16","type":"positive","source":"FDA Orange Book","milestone":"New formulation approved (Hikma)"},{"date":"2019-03-26","type":"positive","source":"DrugCentral","milestone":"PMDA approval (SHIONOGI & Co., Ltd.)"},{"date":"2020-07-30","type":"positive","source":"FDA Orange Book","milestone":"New formulation approved (Dr Reddys)"},{"date":"2021-08-25","type":"positive","source":"FDA Orange Book","milestone":"New formulation approved (Eugia Pharma Speclts)"},{"date":"2023-06-07","type":"positive","source":"FDA Orange Book","milestone":"Frindovyx approved — 1GM/2ML (500MG/ML)"},{"date":"2023-09-12","type":"positive","source":"FDA Orange Book","milestone":"New formulation approved (Sandoz)"}],"aiSummary":"Cytoxan (Lyophilized) is a cyclophosphamide-based chemotherapy medication originally developed by Baxter Healthcare. It is a small molecule that targets the cytochrome P450 3A4 enzyme and has been FDA-approved since 1959 for various types of leukemia and cancer, including adenocarcinoma of the ovary and breast cancer. As an off-patent medication, it is available from multiple generic manufacturers. Key safety considerations include its potential for bone marrow suppression and other hematologic toxicities. Commercially, it is available in a lyophilized form.","brandName":"Cytoxan (Lyophilized)","ecosystem":[{"indication":"Acute lymphoid leukemia, disease","otherDrugs":[],"globalPrevalence":453000},{"indication":"Acute monocytic leukemia","otherDrugs":[],"globalPrevalence":null},{"indication":"Acute myelogenous leukemia","otherDrugs":[],"globalPrevalence":null},{"indication":"Adenocarcinoma of the ovary","otherDrugs":[],"globalPrevalence":null},{"indication":"Burkitt's lymphoma","otherDrugs":[{"name":"dexamethasone","slug":"dexamethasone","company":""},{"name":"doxorubicin","slug":"doxorubicin","company":""},{"name":"methotrexate","slug":"methotrexate","company":"Dava Pharms Inc"},{"name":"rituximab","slug":"rituximab","company":"Genentech"}],"globalPrevalence":null},{"indication":"Carcinoma of breast","otherDrugs":[{"name":"docetaxel","slug":"docetaxel","company":"Sanofi Aventis Us"},{"name":"doxorubicin","slug":"doxorubicin","company":""},{"name":"epirubicin","slug":"epirubicin","company":"Pfizer Inc"},{"name":"everolimus","slug":"everolimus","company":"Novartis"}],"globalPrevalence":160000000},{"indication":"Chronic lymphoid leukemia, disease","otherDrugs":[{"name":"bendamustine","slug":"bendamustine","company":"Cephalon"},{"name":"chlorambucil","slug":"chlorambucil","company":"Aspen Global Inc"},{"name":"duvelisib","slug":"duvelisib","company":"Verastem Inc"},{"name":"fludarabine phosphate","slug":"fludarabine-phosphate","company":""}],"globalPrevalence":null},{"indication":"Chronic myeloid leukemia","otherDrugs":[{"name":"hydroxycarbamide","slug":"hydroxycarbamide","company":"Bristol Myers Squibb"},{"name":"mechlorethamine","slug":"mechlorethamine","company":"Recordati Rare"},{"name":"omacetaxine mepesuccinate","slug":"omacetaxine-mepesuccinate","company":"Ivax Intl"},{"name":"ponatinib","slug":"ponatinib","company":"Ariad"}],"globalPrevalence":480000}],"mechanism":{"target":"Cytochrome P450 3A4","novelty":"Follow-on","targets":[{"gene":"CYP3A4","source":"DrugCentral","target":"Cytochrome P450 3A4","protein":"Cytochrome P450 3A4"}],"modality":"Small Molecule","drugClass":"cyclophosphamide","explanation":"The mechanism of action is thought to involve cross-linking of tumor cell DNA.","oneSentence":"Cytoxan works by interfering with the DNA replication process in rapidly dividing cancer cells.","technicalDetail":"Cytoxan is a nitrogen mustard alkylating agent that forms DNA cross-links and interstrand cross-links, leading to DNA damage and apoptosis in cancer cells.","_target_confidence":0.5},"commercial":{"launchDate":"1959","_launchSource":"DrugCentral (FDA 1959-11-16, BAXTER HLTHCARE)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/758","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CYCLOPHOSPHAMIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CYCLOPHOSPHAMIDE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T02:50:27.895596","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T05:57:10.826237+00:00","fieldsConflicting":8,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"chlorambucil","drugSlug":"chlorambucil","fdaApproval":"1957-03-18","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"melphalan","drugSlug":"melphalan","fdaApproval":"1964-01-17","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"mechlorethamine","drugSlug":"mechlorethamine","fdaApproval":"1949-03-15","patentExpiry":"Mar 7, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ifosfamide","drugSlug":"ifosfamide","fdaApproval":"1988-12-30","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"bendamustine","drugSlug":"bendamustine","fdaApproval":"2008-03-20","patentExpiry":"Sep 26, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"melphalan flufenamide","drugSlug":"melphalan-flufenamide","fdaApproval":"2021-02-26","relationship":"same-class"}],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"cyclophosphamide","indications":{"approved":[{"name":"Acute lymphoid leukemia, disease","source":"DrugCentral","snomedId":91857003,"regulator":"FDA","usPrevalence":null,"globalPrevalence":453000,"prevalenceMethod":"curated","prevalenceSource":"Blood Rev., 2018 (PMID:29174416)"},{"name":"Acute monocytic leukemia","source":"DrugCentral","snomedId":413441006,"regulator":"FDA","eligibility":"Adults and children with acute myelogenous and monocytic leukemia"},{"name":"Acute myelogenous leukemia","source":"DrugCentral","snomedId":359640008,"regulator":"FDA","eligibility":"Adults and children with acute myelogenous and monocytic leukemia"},{"name":"Adenocarcinoma of the ovary","source":"DrugCentral","snomedId":363443007,"regulator":"FDA","eligibility":"Adults with adenocarcinoma of the ovary"},{"name":"Burkitt's lymphoma","source":"DrugCentral","snomedId":118617000,"regulator":"FDA","eligibility":"Adults and children with Burkitt's lymphoma"},{"name":"Carcinoma of breast","source":"DrugCentral","snomedId":254838004,"regulator":"FDA","eligibility":"Adults with carcinoma of the breast","usPrevalence":null,"globalPrevalence":160000000,"prevalenceMethod":"curated","prevalenceSource":"Expert Rev Clin Pharmacol, 2019 (PMID:31287333)"},{"name":"Chronic lymphoid leukemia, disease","source":"DrugCentral","snomedId":92814006,"regulator":"FDA"},{"name":"Chronic myeloid leukemia","source":"DrugCentral","snomedId":92818009,"regulator":"FDA","eligibility":"Adults with chronic granulocytic leukemia","usPrevalence":null,"globalPrevalence":480000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG])"},{"name":"Histiocytic lymphoma","source":"DrugCentral","snomedId":109988003,"regulator":"FDA","eligibility":"Adults and children with histiocytic lymphoma"},{"name":"Hodgkin's disease","source":"DrugCentral","snomedId":118599009,"regulator":"FDA","eligibility":"Adults with Hodgkin's disease (Stages III and IV of the Ann Arbor staging system)"},{"name":"Malignant lymphoma","source":"DrugCentral","snomedId":118600007,"regulator":"FDA"},{"name":"Mixedcell type lymphoma","source":"DrugCentral","snomedId":188676008,"regulator":"FDA"},{"name":"Multiple myeloma","source":"DrugCentral","snomedId":109989006,"regulator":"FDA","usPrevalence":35000,"globalPrevalence":176000,"prevalenceMethod":"curated","prevalenceSource":"IARC GLOBOCAN, 2022"},{"name":"Mycosis fungoides","source":"DrugCentral","snomedId":118618005,"regulator":"FDA","eligibility":"Adults with advanced mycosis fungoides"},{"name":"Neuroblastoma","source":"DrugCentral","snomedId":432328008,"regulator":"FDA","eligibility":"Children with disseminated neuroblastoma","usPrevalence":null,"globalPrevalence":880000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (European Medicines Agency 2018[INST])"},{"name":"Retinoblastoma","source":"DrugCentral","snomedId":370967009,"regulator":"FDA"},{"name":"Systemic AL amyloidosis","source":"DrugCentral","snomedId":23132008,"regulator":"FDA","usPrevalence":null,"globalPrevalence":23200000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet J Rare Dis, 2025 (PMID:39819351)"},{"name":"Treatment prior to tumor-specific T-cell infusion therapy","source":"DrugCentral","snomedId":"","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"currentOwner":"Baxter Hlthcare","drugCategory":"established","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"chlorambucil","brandName":"chlorambucil","genericName":"chlorambucil","approvalYear":"1957","relationship":"same-class"},{"drugId":"melphalan","brandName":"melphalan","genericName":"melphalan","approvalYear":"1964","relationship":"same-class"},{"drugId":"mechlorethamine","brandName":"mechlorethamine","genericName":"mechlorethamine","approvalYear":"1949","relationship":"same-class"},{"drugId":"ifosfamide","brandName":"ifosfamide","genericName":"ifosfamide","approvalYear":"1988","relationship":"same-class"},{"drugId":"bendamustine","brandName":"bendamustine","genericName":"bendamustine","approvalYear":"2008","relationship":"same-class"},{"drugId":"melphalan-flufenamide","brandName":"melphalan flufenamide","genericName":"melphalan flufenamide","approvalYear":"2021","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT04759586","phase":"PHASE3","title":"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-10-05","conditions":["Primary Mediastinal Large B-Cell Lymphoma"],"enrollment":244,"completionDate":"2026-12-31"},{"nctId":"NCT02306161","phase":"PHASE3","title":"Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-12","conditions":["Metastatic Ewing Sarcoma","Metastatic Malignant Neoplasm in the Bone","Metastatic Malignant Neoplasm in the Bone Marrow","Metastatic Malignant Neoplasm in the Lung","Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone","Peripheral Primitive Neuroectodermal Tumor of Soft Tissues"],"enrollment":312,"completionDate":"2026-09-17"},{"nctId":"NCT02436707","phase":"PHASE2","title":"Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2015-10-27","conditions":["Lymphoma"],"enrollment":129,"completionDate":"2026-12-31"},{"nctId":"NCT02579967","phase":"PHASE2","title":"Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-11-19","conditions":["Primary T-cell Immunodeficiency Disorders","Common Variable Immunodeficiency","Immune System Diseases","Autoimmune Lymphoproliferative","Lymphoproliferative Disorders"],"enrollment":354,"completionDate":"2036-12-31"},{"nctId":"NCT06317662","phase":"PHASE2","title":"Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-06-05","conditions":["Acute Leukemia of Ambiguous Lineage","B Acute Lymphoblastic Leukemia"],"enrollment":153,"completionDate":"2028-12-31"},{"nctId":"NCT05702853","phase":"PHASE1,PHASE2","title":"Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2023-11-06","conditions":["B-cell Non Hodgkin Lymphoma","Chronic Lymphocytic Leukemia"],"enrollment":27,"completionDate":"2026-12-30"},{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":["Breast Neoplasms","Triple Negative Breast Neoplasms","HR Low-Positive/HER2-Negative Breast Neoplasms"],"enrollment":2400,"completionDate":"2034-12-29"},{"nctId":"NCT03914625","phase":"PHASE3","title":"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-07-03","conditions":["B Acute Lymphoblastic Leukemia","B Lymphoblastic Lymphoma","Down Syndrome"],"enrollment":6720,"completionDate":"2027-09-30"},{"nctId":"NCT06413498","phase":"PHASE3","title":"A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2024-08-23","conditions":["Multiple Myeloma"],"enrollment":450,"completionDate":"2031-07"},{"nctId":"NCT06154252","phase":"PHASE2,PHASE3","title":"RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy","status":"RECRUITING","sponsor":"Cabaletta Bio","startDate":"2023-12-20","conditions":["Idiopathic Inflammatory Myopathy","Dermatomyositis","Anti-Synthetase Syndrome","Immune-Mediated Necrotizing Myopathy","Juvenile Dermatomyositis","Juvenile Polymyositis","Juvenile Idiopathic Inflammatory Myopathy (JIIM)","Juvenile Myositis"],"enrollment":74,"completionDate":"2028-07"},{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":["Lymphoproliferative Disorder","HHV-8","Malignancy","HIV"],"enrollment":75,"completionDate":"2026-10-01"},{"nctId":"NCT06172296","phase":"PHASE3","title":"Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-04-19","conditions":["Ganglioneuroblastoma, Nodular","Neuroblastoma"],"enrollment":478,"completionDate":"2029-12-31"},{"nctId":"NCT07495631","phase":"NA","title":"Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":["Acute Lymphoblastic Leukemia, Adult"],"enrollment":80,"completionDate":"2030-03-01"},{"nctId":"NCT02567435","phase":"PHASE3","title":"Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-06-01","conditions":["Alveolar Rhabdomyosarcoma","Botryoid-Type Embryonal Rhabdomyosarcoma","Embryonal Rhabdomyosarcoma","Rhabdomyosarcoma","Sclerosing Rhabdomyosarcoma","Spindle Cell Rhabdomyosarcoma"],"enrollment":325,"completionDate":"2026-10-27"},{"nctId":"NCT04301076","phase":"PHASE1","title":"Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (\"EPOCH\") for Adult T-Cell Leukemia-Lymphoma (ATLL)","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-08-31","conditions":["Acute Adult T-Cell Leukemia/Lymphoma","Adult T-Cell Leukemia/Lymphoma","Chronic Adult T-Cell Leukemia/Lymphoma","HTLV-1 Infection"],"enrollment":30,"completionDate":"2027-06-30"},{"nctId":"NCT02166463","phase":"PHASE3","title":"Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-03-19","conditions":["Ann Arbor Stage IIB Hodgkin Lymphoma","Ann Arbor Stage IIIB Hodgkin Lymphoma","Ann Arbor Stage IVA Hodgkin Lymphoma","Ann Arbor Stage IVB Hodgkin Lymphoma","Childhood Hodgkin Lymphoma","Classic Hodgkin Lymphoma"],"enrollment":600,"completionDate":"2026-10-03"},{"nctId":"NCT02443077","phase":"PHASE3","title":"Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2016-10-12","conditions":["Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type","Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type"],"enrollment":94,"completionDate":"2026-12-23"},{"nctId":"NCT06744504","phase":"PHASE3","title":"Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-01-10","conditions":["AML","RUNX1-RUNX1T1 Fusion Protein Expression"],"enrollment":300,"completionDate":"2029-12-01"},{"nctId":"NCT02830724","phase":"PHASE1,PHASE2","title":"Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-04-06","conditions":["Pancreatic Cancer","Renal Cell Cancer","Breast Cancer","Melanoma","Ovarian Cancer"],"enrollment":124,"completionDate":"2028-01-01"},{"nctId":"NCT07494565","phase":"PHASE2","title":"Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-05","conditions":["Diffuse Large B-Cell Lymphoma (DLBCL)","CD5 Positive"],"enrollment":60,"completionDate":"2028-12-31"},{"nctId":"NCT00428142","phase":"PHASE2","title":"Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2007-05-01","conditions":["Lymphoma"],"enrollment":95,"completionDate":"2012-01-06"},{"nctId":"NCT01176006","phase":"PHASE2","title":"Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-10-05","conditions":["DOCK8 Deficiency"],"enrollment":70,"completionDate":"2028-10-31"},{"nctId":"NCT03721068","phase":"PHASE1","title":"Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-02-19","conditions":["Neuroblastoma","Osteosarcoma"],"enrollment":18,"completionDate":"2044-06-19"},{"nctId":"NCT02621021","phase":"PHASE2","title":"A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-12-04","conditions":["Melanoma"],"enrollment":170,"completionDate":"2029-06-16"},{"nctId":"NCT03328026","phase":"PHASE1,PHASE2","title":"Combination Study of SV-BR-1-GM With Retifanlimab","status":"COMPLETED","sponsor":"BriaCell Therapeutics Corporation","startDate":"2018-03-16","conditions":["Breast Cancer","Breast Neoplasm","Metastatic Breast Cancer","Breast Cancer Metastatic"],"enrollment":36,"completionDate":"2026-03-24"},{"nctId":"NCT02180867","phase":"PHASE2,PHASE3","title":"Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-07-11","conditions":["Alveolar Soft Part Sarcoma","Angiomatoid Fibrous Histiocytoma","Atypical Fibroxanthoma","Clear Cell Sarcoma of Soft Tissue","Epithelioid Malignant Peripheral Nerve Sheath Tumor","Epithelioid Sarcoma","Extraskeletal Myxoid Chondrosarcoma","Extraskeletal Osteosarcoma","Fibrohistiocytic Neoplasm","Fibrosarcoma","Inflammatory Myofibroblastic Tumor","Intimal Sarcoma","Leiomyosarcoma","Liposarcoma","Liver Embryonal Sarcoma","Low Grade Fibromyxoid Sarcoma","Low Grade Myofibroblastic Sarcoma","Malignant Peripheral Nerve Sheath Tumor","Malignant Skin Granular Cell Tumor","Malignant Triton Tumor","Mesenchymal Chondrosarcoma","Myxofibrosarcoma","Myxoid Chondrosarcoma","Myxoinflammatory Fibroblastic Sarcoma","Nerve Sheath Neoplasm","PEComa","Pericytic Neoplasm","Plexiform Fibrohistiocytic Tumor","Sclerosing Epithelioid Fibrosarcoma","Skin Glomus Tumor","Stage IB Soft Tissue Sarcoma AJCC v7","Stage IIB Soft Tissue Sarcoma AJCC v7","Stage III Soft Tissue Sarcoma AJCC v7","Stage IV Soft Tissue Sarcoma AJCC v7","Synovial Sarcoma","Undifferentiated High Grade Pleomorphic Sarcoma of Bone"],"enrollment":140,"completionDate":"2026-12-24"},{"nctId":"NCT00792948","phase":"PHASE2","title":"Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09-01","conditions":["Acute Lymphoblastic Leukemia","Adult B Acute Lymphoblastic Leukemia","Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","Adult L1 Acute Lymphoblastic Leukemia","Adult L2 Acute Lymphoblastic Leukemia","Adult T Acute Lymphoblastic Leukemia","Recurrent Adult Acute Lymphoblastic Leukemia"],"enrollment":97,"completionDate":"2027-01-06"},{"nctId":"NCT03269669","phase":"PHASE2","title":"Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-23","conditions":["Grade 1 Follicular Lymphoma","Grade 2 Follicular Lymphoma","Grade 3a Follicular Lymphoma","Recurrent Follicular Lymphoma","Refractory Follicular Lymphoma"],"enrollment":73,"completionDate":"2027-01-21"},{"nctId":"NCT03984448","phase":"PHASE2,PHASE3","title":"Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-10-22","conditions":["Diffuse Large B-Cell Lymphoma","Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Double-Expressor Lymphoma","EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","High Grade B-Cell Lymphoma, Not Otherwise Specified","Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present","Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma"],"enrollment":363,"completionDate":"2028-04-01"},{"nctId":"NCT07297667","phase":"PHASE1","title":"GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours","status":"NOT_YET_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2026-03-01","conditions":["Alveolar Soft Part Sarcoma","Renal Cell Carcinoma","Triple Negative Breast Cancer"],"enrollment":30,"completionDate":"2033-09-01"},{"nctId":"NCT04530565","phase":"PHASE3","title":"Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-25","conditions":["B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1"],"enrollment":348,"completionDate":"2028-07-01"},{"nctId":"NCT00740805","phase":"PHASE1","title":"Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-08-18","conditions":["Ann Arbor Stage III Non-Hodgkin Lymphoma","Ann Arbor Stage IV Non-Hodgkin Lymphoma","Solid Neoplasm"],"enrollment":81,"completionDate":"2026-10-22"},{"nctId":"NCT06904066","phase":"PHASE1","title":"Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":["Malignancy, Hematologic","Neoplasms, Hematologic","Neoplasms, Hematopoietic","Blood Cancer","Hematological Neoplasms","Hematopoietic Malignancies","Dysmyelopoietic Syndromes","Hematopoetic Myelodysplasia","Myeloid Leukemia, Acute","Nonlymphoblastic Leukemia, Acute","Leukemia, Lymphocytic, Acute"],"enrollment":86,"completionDate":"2029-04-30"},{"nctId":"NCT05675410","phase":"PHASE3","title":"A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-05-11","conditions":["Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8"],"enrollment":1875,"completionDate":"2031-04-28"},{"nctId":"NCT01351909","phase":"PHASE1","title":"Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-05-02","conditions":["Locally Advanced Unresectable Breast Carcinoma","Metastatic Breast Carcinoma","Recurrent Breast Carcinoma","Stage IIIB Breast Cancer AJCC v7","Stage IIIC Breast Cancer AJCC v7","Stage IV Breast Cancer AJCC v6 and v7"],"enrollment":35,"completionDate":"2026-03-18"},{"nctId":"NCT05463133","phase":"PHASE1,PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Granulomatous Disease (CGD) With an Alemtuzumab, Busulfan and TBI-based Conditioning Regimen Combined With Cytokine (IL-6, +/- IFN-gamma) Antagonists","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2022-07-08","conditions":["Chronic Granulomatous Disease"],"enrollment":50,"completionDate":"2032-12-31"},{"nctId":"NCT06733935","phase":"PHASE1,PHASE2","title":"A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)","status":"RECRUITING","sponsor":"Nkarta, Inc.","startDate":"2024-11-04","conditions":["Systemic Sclerosis","Idiopathic Inflammatory Myopathies","Antineutrophil Cytoplasmic Antibody-Associated Vasculitis"],"enrollment":144,"completionDate":"2028-10"},{"nctId":"NCT01856192","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-08-27","conditions":["Ann Arbor Stage II Diffuse Large B-Cell Lymphoma","Ann Arbor Stage III Diffuse Large B-Cell Lymphoma","Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma"],"enrollment":349,"completionDate":"2026-12-31"},{"nctId":"NCT06717347","phase":"PHASE3","title":"A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-01-27","conditions":["Diffuse Large B-Cell Lymphoma"],"enrollment":1046,"completionDate":"2032-03-29"},{"nctId":"NCT07444710","phase":"PHASE1","title":"Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-08-20","conditions":["Ann Arbor Stage II Mantle Cell Lymphoma","Ann Arbor Stage III Mantle Cell Lymphoma","Ann Arbor Stage IV Mantle Cell Lymphoma"],"enrollment":16,"completionDate":"2027-09-01"},{"nctId":"NCT07497165","phase":"","title":"Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-11-01","conditions":["Relapsed/Refractory Multiple Myeloma (RRMM)","Multiple Myeloma"],"enrollment":48,"completionDate":"2027-06-30"},{"nctId":"NCT06058377","phase":"PHASE3","title":"Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-11-27","conditions":["Anatomic Stage II Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","HER2-Negative Breast Carcinoma","Hormone Receptor-Positive Breast Carcinoma"],"enrollment":3680,"completionDate":"2026-05-31"},{"nctId":"NCT06060613","phase":"PHASE1,PHASE2","title":"Safety and Efficacy of OBX-115 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Obsidian Therapeutics, Inc.","startDate":"2023-10-25","conditions":["Tumor Skin","Metastatic Melanoma","Melanoma","Lung Cancer","Metastatic Lung Cancer","Non Small Cell Lung Cancer","Metastatic Non Small Cell Lung Cancer"],"enrollment":208,"completionDate":"2028-06-30"},{"nctId":"NCT07444632","phase":"PHASE1","title":"Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/Refractory Lymphoid Malignancies","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-08-31","conditions":["Lymphoid","Hodgkin Lymphoma"],"enrollment":60,"completionDate":"2032-09-30"},{"nctId":"NCT03017820","phase":"PHASE1","title":"A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2017-04-04","conditions":["B-Cell Non-Hodgkin Lymphoma","Histiocytic and Dendritic Cell Neoplasm","Myelodysplastic Syndrome","Previously Treated Myelodysplastic Syndrome","Recurrent Adult Acute Myeloid Leukemia","Recurrent Anaplastic Large Cell Lymphoma","Recurrent Angioimmunoblastic T-Cell Lymphoma","Recurrent Mycosis Fungoides","Recurrent Plasma Cell Myeloma","Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","Recurrent T-Cell Non-Hodgkin Lymphoma","Refractory Acute Myeloid Leukemia","Refractory Anaplastic Large Cell Lymphoma","Refractory Angioimmunoblastic T-Cell Lymphoma","Refractory Mycosis Fungoides","Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified","Refractory Plasma Cell Myeloma","Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma","Refractory T-Cell Non-Hodgkin Lymphoma"],"enrollment":127,"completionDate":"2032-04-01"},{"nctId":"NCT07437963","phase":"PHASE1,PHASE2","title":"Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-05-01","conditions":["Recurrent Ganglioneuroblastoma","Recurrent Neuroblastoma","Refractory Ganglioneuroblastoma","Refractory Neuroblastoma"],"enrollment":76,"completionDate":"2029-09-30"},{"nctId":"NCT06834282","phase":"PHASE1","title":"CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)","status":"RECRUITING","sponsor":"CERo Therapeutics Holdings, Inc.","startDate":"2025-04-07","conditions":["AML","Acute Myeloid Leukemia","Refractory Acute Myeloid Leukemia"],"enrollment":18,"completionDate":"2029-12-31"},{"nctId":"NCT07496229","phase":"PHASE1,PHASE2","title":"Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)","status":"NOT_YET_RECRUITING","sponsor":"Dizal Pharmaceuticals","startDate":"2026-03","conditions":["T-cell Lymphomas"],"enrollment":165,"completionDate":"2029-12"},{"nctId":"NCT05999994","phase":"PHASE2","title":"A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2020-01-22","conditions":["Neoplasms","Child","Adolescent"],"enrollment":105,"completionDate":"2027-05"},{"nctId":"NCT07328503","phase":"PHASE2","title":"CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":["Acute Lymphoblastic Leukemia","B-All"],"enrollment":20,"completionDate":"2031-01-31"},{"nctId":"NCT06847269","phase":"PHASE2","title":"CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2025-05-21","conditions":["Acute Lymphoblastic Leukemia","Refractory Acute Lymphoblastic Leukemia"],"enrollment":25,"completionDate":"2031-04"},{"nctId":"NCT05567198","phase":"","title":"Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires","status":"RECRUITING","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","startDate":"2023-03-03","conditions":["Systemic Lupus Erythematosus (Sle)","Primary Ovarian Insufficiency (Poi)"],"enrollment":100,"completionDate":"2027-05-31"},{"nctId":"NCT05826535","phase":"PHASE1,PHASE2","title":"Study of LYL314 in Aggressive Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Lyell Immunopharma, Inc.","startDate":"2023-05-09","conditions":["Relapsed Non-Hodgkin Lymphoma","Refractory Non-Hodgkin Lymphoma","Non-Hodgkin Lymphoma","Large B-cell Lymphoma"],"enrollment":270,"completionDate":"2031-06-30"},{"nctId":"NCT07493538","phase":"PHASE2","title":"MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases","status":"NOT_YET_RECRUITING","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2026-08","conditions":["AML","MDS","Acute Leukemia","Acute Myeloid Leukemia","Myelodysplastic Syndromes"],"enrollment":132,"completionDate":"2035-03"},{"nctId":"NCT07492628","phase":"PHASE1","title":"Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-03-02","conditions":["Bladder Cancer","Urothelial Carcinoma","Metastatic Urothelial Carcinoma","Locally Advanced Urothelial Carcinoma","Upper Tract Urothelial Carcinoma"],"enrollment":42,"completionDate":"2028-05-17"},{"nctId":"NCT07493148","phase":"PHASE2","title":"Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCL","status":"RECRUITING","sponsor":"Ou Bai, MD/PHD","startDate":"2026-04-30","conditions":["Diffuse Large B-Cell Lymphoma (DLBCL)"],"enrollment":50,"completionDate":"2029-12-30"},{"nctId":"NCT06767046","phase":"PHASE1","title":"KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Corregene Biotechnology Co., Ltd","startDate":"2025-02-18","conditions":["Colorectal","Pancreatic","Non-small Cell Lung Cancer (NSCLC)"],"enrollment":8,"completionDate":"2028-12-31"},{"nctId":"NCT03533816","phase":"PHASE1","title":"Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide","status":"RECRUITING","sponsor":"University of Kansas Medical Center","startDate":"2020-01-31","conditions":["Acute Myeloid Leukemia","Chronic Myeloid Leukemia","Acute Lymphoblastic Leukemia","Myelodysplastic Syndromes"],"enrollment":38,"completionDate":"2028-01"},{"nctId":"NCT07015242","phase":"PHASE2","title":"A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma","status":"RECRUITING","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2025-11-06","conditions":["Lymphoma"],"enrollment":65,"completionDate":"2028-12-10"},{"nctId":"NCT07223021","phase":"PHASE3","title":"A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-10-20","conditions":["B-cell Acute Lymphoblastic Leukemia"],"enrollment":130,"completionDate":"2028-10"},{"nctId":"NCT00576979","phase":"PHASE1,PHASE2","title":"Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2008-03-04","conditions":["Leukemia"],"enrollment":51,"completionDate":"2026-01-07"},{"nctId":"NCT04464434","phase":"PHASE4","title":"Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2020-09-17","conditions":["Systemic Sclerosis","Systemic Scleroses, Diffuse","Scleroderma","Scleroderma, Diffuse","Autologous Stem Cell Transplantation","Cyclophosphamide","Mycophenolate Mofetil","Treatment Strategy"],"enrollment":60,"completionDate":"2026-03-19"},{"nctId":"NCT07489300","phase":"PHASE2","title":"Benmelstobart in Combination With Anlotinib and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Epithelial OvariaN, Fallopian Tube, or Primary Peritoneal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-03-30","conditions":["Ovarian Cancer","Fallopian Tube Cancers","Primary Peritoneal Cancer"],"enrollment":40,"completionDate":"2028-01-31"},{"nctId":"NCT07490275","phase":"PHASE1","title":"Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":["Refractory/Relapsed Systemic Lupus Erythematosus","Refractory / Relapsed / Progressive Systemic Sclerosis","Refractory / Relapsing / Progressive Inflammatory Myopathy","Refractory / Relapsed Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis","Refractory / Relapsed Connective Tissue Disease-Associated Thrombocytopenia"],"enrollment":9,"completionDate":"2028-12-31"},{"nctId":"NCT07491263","phase":"PHASE1","title":"Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Fujian Medical University","startDate":"2026-05-01","conditions":["Relapsed/Refractory CD19-positive B-ALL"],"enrollment":6,"completionDate":"2028-12-31"},{"nctId":"NCT05888493","phase":"PHASE3","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-02","conditions":["Follicular Lymphoma (FL)"],"enrollment":109,"completionDate":"2031-02-20"},{"nctId":"NCT07490041","phase":"EARLY_PHASE1","title":"Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA CAR-NK Cell Injection for the Treatment of Refractory Pediatric Rheumatic Diseases","status":"RECRUITING","sponsor":"The Children's Hospital of Zhejiang University School of Medicine","startDate":"2026-03-19","conditions":["Rheumatic Diseases","Pediatric Rheumatological Condition (i.e., Arthritis, SLE, Kawasaki's Disaese)","Systemic Lupus Erythematosus (SLE)","Connective Tissue Disease-associated Interstitial Lung Disease"],"enrollment":36,"completionDate":"2027-12-19"},{"nctId":"NCT02133196","phase":"PHASE2","title":"T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-10-23","conditions":["Advanced Non-Small Cell Lung Cancer","Squamous Cell Carcinoma","Advanced NSCLC","Adenosquamous Carcinoma","Adenocarcinoma"],"enrollment":85,"completionDate":"2027-10-23"},{"nctId":"NCT07491822","phase":"NA","title":"A Single-Arm, Single-Center, Phase II Clinical Study of Camrelizumab Combined With Radiochemotherapy as Neoadjuvant Therapy for Early-Stage Triple-Negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-03-25","conditions":["TNBC"],"enrollment":43,"completionDate":"2031-03-15"},{"nctId":"NCT03412877","phase":"PHASE2","title":"Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-09-06","conditions":["Endocrine Tumors","Non-Small Cell Lung Cancer","Ovarian Cancer","Breast Cancer","Gastrointestinal/Genitourinary Cancers","Neuroendocrine Tumors","Multiple Myeloma"],"enrollment":285,"completionDate":"2028-03-23"},{"nctId":"NCT01808911","phase":"PHASE3","title":"Outcome of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab (CREHA Study)","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2012-05","conditions":["Acquired Haemophilia"],"enrollment":110,"completionDate":"2021-01-14"},{"nctId":"NCT04990323","phase":"PHASE1,PHASE2","title":"US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies","status":"COMPLETED","sponsor":"ExCellThera inc.","startDate":"2021-12-01","conditions":["High Risk Myeloid Malignancies","Cord Blood Transplant"],"enrollment":13,"completionDate":"2025-12-31"},{"nctId":"NCT03910452","phase":"EARLY_PHASE1","title":"Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-10-28","conditions":["Chronic Granulomatous Disease"],"enrollment":4,"completionDate":"2034-06-15"},{"nctId":"NCT01861106","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-07-24","conditions":["GATA2","Immunodeficiency","MDS"],"enrollment":144,"completionDate":"2028-12-31"},{"nctId":"NCT07224100","phase":"PHASE2","title":"Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma","status":"RECRUITING","sponsor":"University of Washington","startDate":"2026-04-15","conditions":["B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1","B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1","Lymphoblastic Lymphoma"],"enrollment":33,"completionDate":"2028-07-31"},{"nctId":"NCT05003895","phase":"PHASE1","title":"GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-12-08","conditions":["Hepatocellular Carcinoma","Hepatocellular Cancer","Metastatic Hepatocellular Carcinoma"],"enrollment":38,"completionDate":"2027-12-31"},{"nctId":"NCT06871410","phase":"PHASE1","title":"Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2026-03-02","conditions":["Recurrent Acute Myeloid Leukemia","Refractory Acute Myeloid Leukemia"],"enrollment":26,"completionDate":"2028-04-01"},{"nctId":"NCT04677816","phase":"PHASE2","title":"Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2021-10-22","conditions":["Triple Negative Breast Cancer","Vitamin D Deficiency","Invasive Breast Cancer"],"enrollment":50,"completionDate":"2026-08"},{"nctId":"NCT06150651","phase":"PHASE1","title":"Safety of PiggyBac Transposon CAR T-cells Targeting CD-19 in Refractory Lupus.","status":"COMPLETED","sponsor":"Chulalongkorn University","startDate":"2023-12-01","conditions":["SLE (Systemic Lupus)"],"enrollment":3,"completionDate":"2026-03-01"},{"nctId":"NCT02298348","phase":"PHASE1","title":"Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"New Approaches to Neuroblastoma Therapy Consortium","startDate":"2015-10-08","conditions":["Neuroblastoma"],"enrollment":18,"completionDate":"2026-12"},{"nctId":"NCT04103879","phase":"PHASE2","title":"US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia","status":"COMPLETED","sponsor":"ExCellThera inc.","startDate":"2020-11-13","conditions":["High Risk Hematological Malignancy","Cord Blood Transplant"],"enrollment":30,"completionDate":"2026-02-28"},{"nctId":"NCT07487402","phase":"EARLY_PHASE1","title":"Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurrent/Metastatic Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang University","startDate":"2026-03-30","conditions":["Hepatocellular Carcinoma (HCC)"],"enrollment":27,"completionDate":"2029-04-15"},{"nctId":"NCT04799275","phase":"PHASE2,PHASE3","title":"Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2021-05-20","conditions":["Ann Arbor Stage III Diffuse Large B-Cell Lymphoma","Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma","Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma","Diffuse Large B-Cell Lymphoma Activated B-Cell Type","Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation","Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type","Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Grade 3b Follicular Lymphoma","HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements","High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements","High Grade B-Cell Lymphoma, Not Otherwise Specified","Intravascular Large B-Cell Lymphoma","Lymphoplasmacytic Lymphoma","Nodular Lymphocyte Predominant B-Cell Lymphoma","Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type","T-Cell/Histiocyte-Rich Large B-Cell Lymphoma","Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma","Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma"],"enrollment":422,"completionDate":"2027-03-01"},{"nctId":"NCT02654119","phase":"PHASE2","title":"Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2015-12-11","conditions":["HER2 Positive Breast Carcinoma","Stage I Breast Cancer AJCC v7","Stage IA Breast Cancer AJCC v7","Stage IB Breast Cancer AJCC v7","Stage II Breast Cancer AJCC v6 and v7","Stage IIA Breast Cancer AJCC v6 and v7","Stage IIB Breast Cancer AJCC v6 and v7"],"enrollment":20,"completionDate":"2025-12-08"},{"nctId":"NCT02287311","phase":"PHASE1","title":"Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2015-02","conditions":["Hodgkin Disease","Non-Hodgkin Lymphoma","Severe Chronic Active Epstein Barr Virus","T/NK-lymphoproliferative Disease","Nasopharyngeal Carcinoma","Smooth Muscle Tumor"],"enrollment":38,"completionDate":"2029-03"},{"nctId":"NCT07214688","phase":"PHASE2","title":"Fludarabine and Intermediate-dose TBI Followed by PTCy in Patients Undergoing Allo Transplant for Heme Malignancies","status":"RECRUITING","sponsor":"Hackensack Meridian Health","startDate":"2026-01-06","conditions":["Allogeneic Stem Cell Transplant Recipient"],"enrollment":209,"completionDate":"2032-01"},{"nctId":"NCT06528691","phase":"PHASE2","title":"Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2026-04","conditions":["High Grade Glioma","CNS Tumor"],"enrollment":52,"completionDate":"2032-11"},{"nctId":"NCT07487597","phase":"EARLY_PHASE1","title":"Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors","status":"RECRUITING","sponsor":"TCRCure Biopharma Ltd.","startDate":"2026-02-28","conditions":["Solid Tumor"],"enrollment":24,"completionDate":"2029-02-28"},{"nctId":"NCT00338377","phase":"PHASE2","title":"Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-02-01","conditions":["Melanoma"],"enrollment":1230,"completionDate":"2030-02-28"},{"nctId":"NCT03570892","phase":"PHASE3","title":"Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-05-07","conditions":["Non-Hodgkin Lymphoma"],"enrollment":331,"completionDate":"2026-02-03"},{"nctId":"NCT06831955","phase":"PHASE2","title":"LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2026-02-01","conditions":["Triple Negative Breast Cancer (TNBC), Early Setting"],"enrollment":356,"completionDate":"2031-09-01"},{"nctId":"NCT07486089","phase":"PHASE1,PHASE2","title":"Dual-Target CAR-NK Cells for Advanced Breast Cancer (HER2+ and TNBC)","status":"RECRUITING","sponsor":"Beijing Biotech","startDate":"2026-02-02","conditions":["Breast Cancer (Locally Advanced or Metastatic)","HER2-positive Breast Cancer","Triple-Negative Breast Cancer (TNBC)"],"enrollment":60,"completionDate":"2028-03-17"},{"nctId":"NCT07215585","phase":"PHASE3","title":"AZD0486 1L Therapy for Elderly or Unfit Participants With LBCL","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-11","conditions":["Large B-cell Lymphoma"],"enrollment":420,"completionDate":"2033-07-28"},{"nctId":"NCT07169851","phase":"PHASE2","title":"A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-11-28","conditions":["Nausea","Vomiting","Drug-Related Side Effects and Adverse Reactions","Neoplasms"],"enrollment":204,"completionDate":"2026-09"},{"nctId":"NCT05436418","phase":"PHASE1,PHASE2","title":"The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-11-18","conditions":["Peripheral Blood Stem Cell Transplantation","Hematopoietic Stem Cell Transplantation"],"enrollment":260,"completionDate":"2028-06-25"},{"nctId":"NCT06890884","phase":"PHASE2","title":"A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-04-11","conditions":["Lymphoma, Large B-Cell, Diffuse"],"enrollment":594,"completionDate":"2032-12-16"},{"nctId":"NCT03420963","phase":"PHASE1","title":"Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-08-31","conditions":["Recurrent Cutaneous Melanoma","Recurrent Lip and Oral Cavity Carcinoma","Recurrent Malignant Endocrine Neoplasm","Recurrent Malignant Female Reproductive System Neoplasm","Recurrent Malignant Male Reproductive System Neoplasm","Recurrent Malignant Mesothelioma","Recurrent Malignant Neoplasm of Multiple Primary Sites","Recurrent Malignant Oral Neoplasm","Recurrent Malignant Pharyngeal Neoplasm","Recurrent Malignant Skin Neoplasm","Recurrent Malignant Soft Tissue Neoplasm","Recurrent Malignant Solid Neoplasm","Recurrent Malignant Thyroid Gland Neoplasm","Recurrent Malignant Urinary System Neoplasm","Refractory Cutaneous Melanoma","Refractory Malignant Bone Neoplasm","Refractory Malignant Endocrine Neoplasm","Refractory Malignant Female Reproductive System Neoplasm","Refractory Malignant Male Reproductive System Neoplasm","Refractory Malignant Mesothelioma","Refractory Malignant Neoplasm of Multiple Primary Sites","Refractory Malignant Oral Neoplasm","Refractory Malignant Pharyngeal Neoplasm","Refractory Malignant Skin Neoplasm","Refractory Malignant Soft Tissue Neoplasm","Refractory Malignant Solid Neoplasm","Refractory Malignant Thyroid Gland Neoplasm","Refractory Malignant Urinary System Neoplasm"],"enrollment":12,"completionDate":"2026-02-26"},{"nctId":"NCT07101432","phase":"PHASE1","title":"Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in Patients With Advanced Head and Neck Cancer (RADIANCE-NK)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-11-04","conditions":["Head and Neck Cancer"],"enrollment":33,"completionDate":"2029-12-31"},{"nctId":"NCT05359211","phase":"PHASE1","title":"NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2022-12-08","conditions":["Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Recurrent Grade 3b Follicular Lymphoma","Recurrent Primary Mediastinal Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified","Refractory Grade 3b Follicular Lymphoma","Refractory Primary Mediastinal Large B-Cell Lymphoma","Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma"],"enrollment":27,"completionDate":"2026-09-04"},{"nctId":"NCT07101588","phase":"PHASE4","title":"Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-01-01","conditions":["Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)"],"enrollment":200,"completionDate":"2028-12-30"}],"whoEssential":true,"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Capsule, Injection, Tablet","formulations":[{"form":"CAPSULE","route":"ORAL","productName":"CYCLOPHOSPHAMIDE"},{"form":"CAPSULE","route":"ORAL","productName":"Cyclophosphamide"},{"form":"CAPSULE","route":"ORAL","productName":"Cyclophosphamide"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"Cyclophosphamide"},{"form":"INJECTION, POWDER, FOR SOLUTION","route":"INTRAVENOUS","productName":"CYCLOPHOSPHAMIDE"},{"form":"INJECTION, POWDER, FOR SOLUTION","route":"INTRAVENOUS","productName":"Cyclophosphamide"},{"form":"INJECTION, POWDER, FOR SOLUTION","route":"ORAL","productName":"Cyclophosphamide"},{"form":"TABLET","route":"ORAL","productName":"Cyclophosphamide"},{"form":"TABLET","route":"ORAL","productName":"Cyclophosphamide"},{"form":"TABLET","route":"ORAL","productName":"Cyclophosphamide"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000146452","MMSL":"31952","NDDF":"002631","UNII":"8N3DW7272P","VUID":"4018114","CHEBI":"CHEBI:4026","VANDF":"4018114","RXNORM":"3002","UMLSCUI":"C0010583","chemblId":"CHEMBL1200796","ChEMBL_ID":"CHEMBL88","KEGG_DRUG":"D00287","DRUGBANK_ID":"DB00531","PUBCHEM_CID":"2907","SNOMEDCT_US":"387420009","IUPHAR_LIGAND_ID":"7154","SECONDARY_CAS_RN":"6055-19-2","MESH_DESCRIPTOR_UI":"D003520"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1959-","companyName":"Baxter Hlthcare","relationship":"Original Developer"},{"period":"2019","companyName":"SHIONOGI & Co., Ltd.","relationship":"PMDA Licensee"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"8.0 hours","clearance":"1.1 mL/min/kg","bioavailability":"74%","fractionUnbound":"0.87%","volumeOfDistribution":"0.73 L/kg"},"publicationCount":60157,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01AA01","allCodes":["L01AA01"]},"biosimilarFilings":[],"originalDeveloper":"Baxter Hlthcare","recentPublications":[{"date":"2026 Mar 29","pmid":"41904946","title":"Autoimmune Encephalitis in Acute Care-Pathology, Diagnosis, and Management.","journal":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)"},{"date":"2026 Mar 15","pmid":"41904851","title":"IL-17/Th17-Treg Axis regulation by Huangqi Gancao decoction in immunosuppression: Integrating network pharmacology, metabolomics, and in vivo validation.","journal":"Journal of chromatography. B, Analytical technologies in the biomedical and life sciences"},{"date":"2026 Mar 4","pmid":"41904054","title":"Germ layer specification and organotropism in lymphoma invasion.","journal":"Science bulletin"},{"date":"2026","pmid":"41902667","title":"Electroacupuncture Ameliorates Cyclophosphamide-Induced Ovarian Impairment in Rats With Diminished Ovarian Reserve and is Associated With Th17/Treg-Related Immune Modulation.","journal":"Mediators of inflammation"},{"date":"2026 Mar 12","pmid":"41899096","title":"Identification of Drug Repurposing Opportunities of Immunomodulatory Drugs for Inflammatory Bowel Disease Through Inverse Pharmacovigilance Signal Detection in the FAERS Database.","journal":"Journal of clinical medicine"}],"companionDiagnostics":[],"genericManufacturers":19,"_genericFilersChecked":true,"genericManufacturerList":["Alembic","Amneal","Ani Pharms","Baxter Hlthcare","Bedford","Cipla","Eirgen","Epic Pharma Llc","Hainan Poly","Hengrui Pharma","Hikma","Nexus","Roxane","Sagent Pharms Inc","Senores Pharms","Sunny","Teva Parenteral","Xgen Pharms","Zydus Lifesciences"],"status":"approved","companyName":"Baxter Hlthcare","companyId":"baxter","modality":"Small molecule","firstApprovalDate":"1959","enrichmentLevel":4,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"9662342","territory":"US","patent_type":"Formulation","expiry_date":"2035-06-26T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10849916","territory":"US","patent_type":"Formulation","expiry_date":"2035-07-13T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11382923","territory":"US","patent_type":"Formulation","expiry_date":"2035-12-01T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"12329767","territory":"US","patent_type":"Formulation","expiry_date":"2036-02-15T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10993952","territory":"US","patent_type":"Formulation","expiry_date":"2036-02-15T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T05:57:10.826237+00:00","fieldsConflicting":8,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}